Centene Q4 2025 Centene Corp Earnings Call | AllMind AI Earnings | AllMind AI
Q4 2025 Centene Corp Earnings Call
Operator: Good day, and welcome to the Centene Corporation Q4 and full year 2025 earnings conference call. All participants will be in listen-only mode. If you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad, and to withdraw your question, please press star then two. Please note today's event is being recorded. I would now like to turn the conference over to Jennifer Gilligan, Senior Vice President, Investor Relations. Please go ahead.
Operator: Good day, and welcome to the Centene Corporation Q4 and full year 2025 earnings conference call. All participants will be in listen-only mode. If you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad, and to withdraw your question, please press star then two. Please note today's event is being recorded. I would now like to turn the conference over to Jennifer Gilligan, Senior Vice President, Investor Relations. Please go ahead.
Jennifer Gilligan: Thank you, Rocco, and good morning, everyone. Thank you for joining us on our fourth quarter and year-end 2025 earnings results conference call. Sarah London, Chief Executive Officer, and Drew Asher, Executive Vice President and Chief Financial Officer of Centene, will host this morning's call, which also can be accessed through our website at centene.com. Also, guidance slides can be found on our website alongside the webcast. Any remarks that Centene may make about future expectations, plans, and prospects constitute forward-looking statements for the purpose of the Safe Harbor Provision under the Private Securities Litigation Reform Act of 1995. Specifically, our commentary on 2026, including drivers of Adjusted Diluted Earnings Per Share for 2026, are forward-looking statements.
Jennifer Gilligan: Thank you, Rocco, and good morning, everyone. Thank you for joining us on our fourth quarter and year-end 2025 earnings results conference call. Sarah London, Chief Executive Officer, and Drew Asher, Executive Vice President and Chief Financial Officer of Centene, will host this morning's call, which also can be accessed through our website at centene.com. Also, guidance slides can be found on our website alongside the webcast. Any remarks that Centene may make about future expectations, plans, and prospects constitute forward-looking statements for the purpose of the Safe Harbor Provision under the Private Securities Litigation Reform Act of 1995. Specifically, our commentary on 2026, including drivers of Adjusted Diluted Earnings Per Share for 2026, are forward-looking statements.
Jennifer Gilligan: Actual results may differ materially from those indicated by those forward-looking statements as a result of various important factors, including those discussed in our fourth quarter and year-end 2025 press release and 2026 guidance presentation filed this morning, and other public SEC filings, which are available on the company's website under the Investor section. Centene anticipates that subsequent events and developments may cause its estimates to change. While the company may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. The call will also refer to certain non-GAAP measures. A reconciliation of these measures with the most directly comparable GAAP measures can be found in our fourth quarter and year-end 2025 press release and 2026 guidance presentation. With that, I would like to turn the call over to our CEO, Sarah London. Sarah?
Jennifer Gilligan: Actual results may differ materially from those indicated by those forward-looking statements as a result of various important factors, including those discussed in our fourth quarter and year-end 2025 press release and 2026 guidance presentation filed this morning, and other public SEC filings, which are available on the company's website under the Investor section. Centene anticipates that subsequent events and developments may cause its estimates to change. While the company may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. The call will also refer to certain non-GAAP measures. A reconciliation of these measures with the most directly comparable GAAP measures can be found in our fourth quarter and year-end 2025 press release and 2026 guidance presentation.
Jennifer Gilligan: With that, I would like to turn the call over to our CEO, Sarah London. Sarah?
Sarah London: Thank you, Jen, and thanks everyone for joining us. This morning, we reported a Q4 adjusted diluted loss per share of $1.19, contributing to our full year 2025 adjusted diluted EPS of $2.08. While 2025 was undeniably challenging, disciplined execution enabled us to close the year slightly ahead of the expectations we outlined on our Q3 call. Medicaid profitability improved, strengthening the trajectory of our largest business. Underlying medical cost trend within Marketplace and across the Medicare segment was in line to slightly favorable as we closed out Q4, and both segments delivered 2026 enrollment results consistent with our expectations, creating a solid foundation for next year's earnings power. As we look to 2026, we are positioned to deliver meaningful margin improvement and renewed adjusted EPS growth.
Sarah London: Thank you, Jen, and thanks everyone for joining us. This morning, we reported a Q4 adjusted diluted loss per share of $1.19, contributing to our full year 2025 adjusted diluted EPS of $2.08. While 2025 was undeniably challenging, disciplined execution enabled us to close the year slightly ahead of the expectations we outlined on our Q3 call. Medicaid profitability improved, strengthening the trajectory of our largest business. Underlying medical cost trend within Marketplace and across the Medicare segment was in line to slightly favorable as we closed out Q4, and both segments delivered 2026 enrollment results consistent with our expectations, creating a solid foundation for next year's earnings power. As we look to 2026, we are positioned to deliver meaningful margin improvement and renewed adjusted EPS growth.
This morning, we've reported a fourth quarter adjusted diluted loss per share of $1.19, contributing to our full year 2025 adjusted diluted EPS of $28.
While 2025 was undeniably challenging disciplined execution enabled us to close the year. Slightly ahead of the expectations. We outlined on our third quarter call
Medicaid profitability improved, strengthening the trajectory of our largest business.
Underlying medical cost Trend within Marketplace and across the Medicare segment, was in line to slightly favorable, as we closed out Q4. And both segments, delivered 2026, enrollment results. Consistent with our expectations creating a solid foundation for next year's earnings power.
Sarah London: We expect full year 2026 adjusted EPS to be greater than $3, representing more than 40% year-over-year growth and marking important progress toward restoring the enterprise's embedded earnings power. This outlook incorporates Medicaid margin stability, significant margin recovery within our Marketplace business, and continued progress towards our goal of breakeven in Medicare Advantage. Now let's take a look at our business lines, beginning with Medicaid. As an organization, we have been laser-focused on restoring our Medicaid business to sustainable profitability while maintaining our focus on quality outcomes for our members and the communities we serve. As a result of strong cross-enterprise execution, we demonstrated significant progress on this mission in the back half of 2025, with continued momentum through Q4.
Sarah London: We expect full year 2026 adjusted EPS to be greater than $3, representing more than 40% year-over-year growth and marking important progress toward restoring the enterprise's embedded earnings power. This outlook incorporates Medicaid margin stability, significant margin recovery within our Marketplace business, and continued progress towards our goal of breakeven in Medicare Advantage. Now let's take a look at our business lines, beginning with Medicaid. As an organization, we have been laser-focused on restoring our Medicaid business to sustainable profitability while maintaining our focus on quality outcomes for our members and the communities we serve. As a result of strong cross-enterprise execution, we demonstrated significant progress on this mission in the back half of 2025, with continued momentum through Q4.
As we looked at 2026, we are positioned to deliver meaningful, margin Improvement and renewed adjusted EPS growth.
We expect full year, 2026, adjusted EPS to be greater than 3 dollars representing more than 40% year-over-year growth and marking important progress. Toward restoring the Enterprises embedded earnings power.
Now, let's take a look at our business lines, beginning with Medicaid.
As an organization, we have been laser focused on restoring our Medicaid business to sustainable profitability. While maintaining our focus on quality outcomes for our members and the communities, we serve
Sarah London: Our Q4 health benefits ratio of 93.0 was consistent with expectations we set for investors in October, representing 40 basis points of sequential improvement and 190 basis points of improvement from Q2 levels. While flu drove significant national media coverage, flu and influenza-related illness cost within Medicaid were consistent with the elevated expectations we had incorporated into our financial outlook. Trend patterns remained largely consistent in Q4 compared to Q3, with behavioral health still driving roughly half of excess trend and both home health and high cost drugs as secondary pressure points.
Sarah London: Our Q4 health benefits ratio of 93.0 was consistent with expectations we set for investors in October, representing 40 basis points of sequential improvement and 190 basis points of improvement from Q2 levels. While flu drove significant national media coverage, flu and influenza-related illness cost within Medicaid were consistent with the elevated expectations we had incorporated into our financial outlook. Trend patterns remained largely consistent in Q4 compared to Q3, with behavioral health still driving roughly half of excess trend and both home health and high cost drugs as secondary pressure points.
As a result of strong cross Enterprise execution. We demonstrated significant progress on this mission, in the back half of 2025 with continued momentum through Q4.
Our fourth quarter, health benefits ratio of 9300 was consistent with expectations. We set for investors in October representing, 40 basis points of sequential Improvement and 190 basis points of improvement from Q2 levels.
While flu drove significant, National media coverage, flu and influenza related illness cost within Medicaid were consistent with the elevated. Expectations, we had incorporated into our financial Outlook
Sarah London: As we head into 2026, we continue to organize around the key levers that will drive improvement in the Medicaid business, including optimizing our networks for cost and quality performance, thoughtful implementation of new and enhanced clinical programs, rate advocacy, and collaboration with our state partners on program reform, increasing vigilance in our detection and reduction of unnecessary utilization, and a more aggressive approach to fraud within the provider ecosystem in service of our mandate to protect Medicaid program integrity. Our Applied Behavioral Analytics, or ABA Task Force, established in Q2 of 2025, is a perfect example of how we have pulled critical levers to manage costs on behalf of our state partners, while improving the quality of member care at the same time. Leveraging Centene's scale and reach, the team analyzed our ABA data across our 29-state footprint.
Sarah London: As we head into 2026, we continue to organize around the key levers that will drive improvement in the Medicaid business, including optimizing our networks for cost and quality performance, thoughtful implementation of new and enhanced clinical programs, rate advocacy, and collaboration with our state partners on program reform, increasing vigilance in our detection and reduction of unnecessary utilization, and a more aggressive approach to fraud within the provider ecosystem in service of our mandate to protect Medicaid program integrity. Our Applied Behavioral Analytics, or ABA Task Force, established in Q2 of 2025, is a perfect example of how we have pulled critical levers to manage costs on behalf of our state partners, while improving the quality of member care at the same time. Leveraging Centene's scale and reach, the team analyzed our ABA data across our 29-state footprint.
Trend patterns remained largely consistent in Q4 compared to Q3, with Behavioral Health still driving roughly half of excess trend, and both home health and high-cost drugs as secondary pressure points.
As we head into 2026, we continue to organize around the key levers, that will drive Improvement in the Medicaid business, including optimizing our networks for cost and quality performance, thoughtful, implementation of new and enhanced clinical programs rate, advocacy and collaboration with our state Partners on program reform.
Increasing vigilance in our detection and reduction of unnecessary utilization, and a more aggressive approach to fraud within the provider ecosystem, in service of our mandate to protect Medicaid program integrity.
our applied behavioral analytics or ABA task force established in Q2 of 2025 is a perfect example of how we have pulled critical levers to manage costs on behalf of our state Partners, while improving the quality of member Care at the same time,
Sarah London: What we found were consistent patterns of outlier providers with volume versus outcomes-driven care patterns, where the maximum number of hours are prescribed for every patient instead of an individualized care plan. We found children who had been in therapy for 5 to 10 years, where clinical evidence suggests the optimal duration is 2 to 3 years, as well as those enrolled in 40 hours per week of therapy instead of balanced school-integrated care. And we saw a lack of appropriate board-certified oversight of registered behavior technicians. These dynamics drive cost in the system, but far more importantly, they are red flags relative to the quality of patient care for a very vulnerable population. Centene's approach has been data-driven and multi-pronged. We engage directly with providers on gaps we see and focus our networks on providers who follow evidence-based best practices.
Sarah London: What we found were consistent patterns of outlier providers with volume versus outcomes-driven care patterns, where the maximum number of hours are prescribed for every patient instead of an individualized care plan. We found children who had been in therapy for 5 to 10 years, where clinical evidence suggests the optimal duration is 2 to 3 years, as well as those enrolled in 40 hours per week of therapy instead of balanced school-integrated care. And we saw a lack of appropriate board-certified oversight of registered behavior technicians. These dynamics drive cost in the system, but far more importantly, they are red flags relative to the quality of patient care for a very vulnerable population. Centene's approach has been data-driven and multi-pronged. We engage directly with providers on gaps we see and focus our networks on providers who follow evidence-based best practices.
Leveraging Centene's scale and reach, the team analyzed our ABA data across our 29-state footprint,
what we found were consistent, patterns of outlier providers, with volume versus outcomes, driven care patterns, where the maximum number of hours are prescribed for every patient, instead of an individualized care plan,
we found children who had been in therapy for 5 to 10 years where clinical evidence suggests. The optimal duration is 2 to 3 years as well as those enrolled in 40 hours per week of therapy instead of balanced School integrated care.
And we saw a lack of appropriate board, certified oversight of registered Behavior technicians.
These dynamics drive cost in the system. But far more importantly, they are red flags relative to the quality of patient care for a very vulnerable population.
17's approach has been data-driven and multi-pronged.
Sarah London: We meet directly with our state partners to share data, inform program design, and reduce outlier payments. We launched an ABA-specific engagement program to support members, their parents, and their providers. These programs are developed and led by PhD-level board-certified behavioral analysts who are still practicing. So this is not algorithmic or theoretical for us. It is about being responsible stewards of taxpayer dollars and transforming the health of the communities we serve, one kiddo at a time, in this case. Rates continued to be another powerful and important tool to ensure program sustainability. On this front, we closed 2025 with a composite rate adjustment of approximately 5.5% above 2024 levels, consistent with our prior commentary.
Sarah London: We meet directly with our state partners to share data, inform program design, and reduce outlier payments. We launched an ABA-specific engagement program to support members, their parents, and their providers. These programs are developed and led by PhD-level board-certified behavioral analysts who are still practicing. So this is not algorithmic or theoretical for us. It is about being responsible stewards of taxpayer dollars and transforming the health of the communities we serve, one kiddo at a time, in this case. Rates continued to be another powerful and important tool to ensure program sustainability. On this front, we closed 2025 with a composite rate adjustment of approximately 5.5% above 2024 levels, consistent with our prior commentary.
We engage directly with providers on gaps. We see and focus. Our networks on providers who follow evidence-based best practices.
We meet directly with our state Partners to share data inform program design and reduce outlier payments.
And we launched an ABA-specific engagement program to support members, their parents, and their providers.
These programs are developed and led by PhD level board, certified behavioral analysts who are still practicing. So this is not algorithmic or theoretical for us, it is about being responsible stewards of taxpayer dollars and transforming the health of the communities, we serve 1 kiddo at a time in this case,
Rates continue to be another powerful and important tool to ensure program sustainability.
Sarah London: 2021 final rates were in line with our expectations, and as the underlying data naturally rolls forward, we believe rate decisions will increasingly be made on data that reflects the acuity and trend dynamics we have experienced in Medicaid over the last two years. We will continue to be proactive in our engagement and data sharing as we move through 2026 and prepare for 2027 program changes. Standing here today, we have greater visibility into the drivers of our core business and command of the levers needed to drive earnings recovery in Medicaid over the next few years, while maintaining and improving the quality of our care our members receive. Turning to Marketplace. Fundamental medical cost trend for our Marketplace business came in slightly better than expectations in Q4.
Sarah London: 2021 final rates were in line with our expectations, and as the underlying data naturally rolls forward, we believe rate decisions will increasingly be made on data that reflects the acuity and trend dynamics we have experienced in Medicaid over the last two years. We will continue to be proactive in our engagement and data sharing as we move through 2026 and prepare for 2027 program changes. Standing here today, we have greater visibility into the drivers of our core business and command of the levers needed to drive earnings recovery in Medicaid over the next few years, while maintaining and improving the quality of our care our members receive. Turning to Marketplace. Fundamental medical cost trend for our Marketplace business came in slightly better than expectations in Q4.
On this front, we closed 2025 with a composite rate adjustment of approximately 5 and a half percent above 2024 levels consistent with our prior commentary.
1 1, final rates were in line with our expectation. And as the underlying data naturally rolls forward we believe rate decisions will increasingly be made on data that reflects the Acuity and Trend Dynamics. We have experienced in Medicaid over the last 2 years.
We will continue to be proactive in our engagement and data sharing. As we move through 2026 and prepare for 2027 program changes,
standing here today we have greater visibility into the drivers of our Core Business and command of the levers needed to drive earnings recovery in Medicaid, over the next few years while maintaining and improving the quality of our care, our members receive
Turning to Marketplace.
Sarah London: In December, we also received an updated view of the 2025 Wakely data, which showed favorable development relative to our reserve. We experienced two out-of-period items in the quarter, including a 2023 CMS reconciliation and costs related to No Surprises Act disputes. This prompted us to add an accrual for further NSA development related to 2025 dates of service, which ultimately pushed the segment HBR up by roughly 100 basis points versus our original expectations. We have accounted for estimated 2026 NSA costs in our guidance. While the No Surprises Act was designed to protect consumers, it has increasingly become weaponized by market participants looking to extract profits from the system through the Independent Dispute Resolutions, or IDR, process. We are vocal in advocating for NSA reform, and in the meantime, we'll be taking a more proactive, litigious posture as necessary.
Sarah London: In December, we also received an updated view of the 2025 Wakely data, which showed favorable development relative to our reserve. We experienced two out-of-period items in the quarter, including a 2023 CMS reconciliation and costs related to No Surprises Act disputes. This prompted us to add an accrual for further NSA development related to 2025 dates of service, which ultimately pushed the segment HBR up by roughly 100 basis points versus our original expectations. We have accounted for estimated 2026 NSA costs in our guidance. While the No Surprises Act was designed to protect consumers, it has increasingly become weaponized by market participants looking to extract profits from the system through the Independent Dispute Resolutions, or IDR, process. We are vocal in advocating for NSA reform, and in the meantime, we'll be taking a more proactive, litigious posture as necessary.
Fundamental medical cost trend for our Marketplace business came in slightly better than expectations in Q4, in December. We also received an updated view of the 2025 weekly data, which showed favorable development relative to our reserve.
We experienced 2 out of period items in the quarter, including a 2023, CMS reconciliation and costs related to no surprises act disputes.
Up by roughly 100 basis points versus our original expectations.
We have accounted for estimated 2026 NSA costs in our guidance.
While the No Surprises Act was designed to protect consumers, it has increasingly become weaponized by market participants looking to extract profits from the system through the independent dispute resolution, or IDR, process.
Sarah London: As an example, earlier this week, we filed a multimillion-dollar lawsuit against a New York provider alleging fraudulent manipulation of in-network and out-of-network claims. We will continue to take aggressive action to protect the system from fraudulent and abusive exploitation of NSA loopholes. Turning to 2026, the Marketplace team executed incredibly well over the last few months in a dynamic open enrollment period, investing in additional operational support to care for a customer base, navigating significant change and uncertainty. In the absence of congressional intervention, enhanced advanced premium tax credits expired at the end of 2025. As a reminder, we accounted for this assumption and the impact it would have on the market risk pool and cost in our 2026 pricing.
Sarah London: As an example, earlier this week, we filed a multimillion-dollar lawsuit against a New York provider alleging fraudulent manipulation of in-network and out-of-network claims. We will continue to take aggressive action to protect the system from fraudulent and abusive exploitation of NSA loopholes. Turning to 2026, the Marketplace team executed incredibly well over the last few months in a dynamic open enrollment period, investing in additional operational support to care for a customer base, navigating significant change and uncertainty. In the absence of congressional intervention, enhanced advanced premium tax credits expired at the end of 2025. As a reminder, we accounted for this assumption and the impact it would have on the market risk pool and cost in our 2026 pricing.
We are vocal and advocating for NSA reform and in the meantime we'll be taking a more proactive litigious. Posture as necessary, as an example earlier this week, we filed a multi-million dollar lawsuit. Against the New York provider alleging fraudulent manipulation of in network and out of network claims.
we will continue to take aggressive action to protect the system from fraudulent and abusive exploitation of NSA loopholes
turning to 2026.
In the absence of congressional intervention, enhanced Advanced premium tax credits expired, at the end of 2025.
Sarah London: Ambetter membership developed in line with expectations, and we are on track for Q1 ending membership of roughly 3.5 million members, as compared to our December membership of 5.5 million. While market sign-ups are being reported publicly, this isn't the most helpful indicator of true market dynamics. Now that we are into February, paid membership is the most important metric for planning and forecasting. Through the end of January, Ambetter paid rates, while below historical levels, are right in line with our expectations in a post-EAPTC environment. Relative to member demographics, our membership is more notably enrolled in Bronze plans for 2026 compared to prior years, with many of those members still able to access $0 premium products.
Sarah London: Ambetter membership developed in line with expectations, and we are on track for Q1 ending membership of roughly 3.5 million members, as compared to our December membership of 5.5 million. While market sign-ups are being reported publicly, this isn't the most helpful indicator of true market dynamics. Now that we are into February, paid membership is the most important metric for planning and forecasting. Through the end of January, Ambetter paid rates, while below historical levels, are right in line with our expectations in a post-EAPTC environment. Relative to member demographics, our membership is more notably enrolled in Bronze plans for 2026 compared to prior years, with many of those members still able to access $0 premium products.
As a reminder, we accounted for this assumption and the impact it would have on the market risk pool and cost in our 2026 pricing.
And better membership developed in line with expectations. And we are on track for first quarter ending membership of roughly 3 and a half million members as compared to our December membership of 5 and a half million.
While markets signups are being reported publicly. This isn't the most helpful indicator of true market dynamics.
Now that we are into February paid membership is the most important metric for planning and forecasting.
Through the end of January and better paid rates while below historical levels are right in line with our expectations in a post eapc environment.
Sarah London: Bronze membership will represent a little over 30% of our Marketplace enrollment this year, compared to a range of 19% to 24% over the past 4 years. Age and gender demographics remain consistent with recent years. Risk adjustment was obviously a source of significant deviation from our financial plans last year. As you think about the expectations incorporated into our 2026 plan, we anticipate being in a meaningful, payable position for the 2026 plan year at this time. Consistent with other years, we will reassess our risk adjustment position and assumptions as we move through the year and receive additional data.
Sarah London: Bronze membership will represent a little over 30% of our Marketplace enrollment this year, compared to a range of 19% to 24% over the past 4 years. Age and gender demographics remain consistent with recent years. Risk adjustment was obviously a source of significant deviation from our financial plans last year. As you think about the expectations incorporated into our 2026 plan, we anticipate being in a meaningful, payable position for the 2026 plan year at this time. Consistent with other years, we will reassess our risk adjustment position and assumptions as we move through the year and receive additional data.
Relative to member demographics. Our membership is more notably enrolled in bronze plans for 2026 compared to Prior years, with many of those members, still able to access zero dollar premium products.
Bronze Membership will represent a little over 30% of our Marketplace enrollment this year, compared to a range of 19% to 24% over the past four years.
Age and gender demographics remain consistent with recent years.
Risk adjustment was obviously a source of significant deviation from our financial plans last year.
As you think about the expectations incorporated into our 2026 plan, we anticipate being in a meaningful payable position for the 2026 plan year. At this time,
Sarah London: To that end, in an effort to drive additional visibility at an industry level, we are pleased to have worked closely with Wakely, the independent actuarial firm, to support publication of a new report reflecting market-wide paid membership, metallic tier distribution, and statewide average premium, set to be released toward the end of Q1 in order to help market participants better inform risk adjustment assumptions going forward. While 2025 was a difficult year for the marketplace business, we believe the actions we took in the back half of 2025 set us up to navigate 2026 with increased visibility and confidence. We continue to advocate for program reform that will drive affordability and further stabilize the individual marketplace overall, as an alternative to employer-sponsored insurance and a solution for small business owners and other hardworking Americans and their families. Finally, Medicare. Our Medicare segment delivered strong results throughout 2025.
Sarah London: To that end, in an effort to drive additional visibility at an industry level, we are pleased to have worked closely with Wakely, the independent actuarial firm, to support publication of a new report reflecting market-wide paid membership, metallic tier distribution, and statewide average premium, set to be released toward the end of Q1 in order to help market participants better inform risk adjustment assumptions going forward. While 2025 was a difficult year for the marketplace business, we believe the actions we took in the back half of 2025 set us up to navigate 2026 with increased visibility and confidence. We continue to advocate for program reform that will drive affordability and further stabilize the individual marketplace overall, as an alternative to employer-sponsored insurance and a solution for small business owners and other hardworking Americans and their families.
Consistent with other years, we will reassess our risk adjustment position and assumptions as we move through the year and receive additional data.
To that end, in an effort to drive additional visibility at an industry level, we are pleased to have worked closely with Weekly, the independent actuarial firm, to support publication of a new report reflecting market-wide paid membership metallic tier distribution and statewide average premium, set to be released toward the end of Q1. This is in order to help market participants better inform risk adjustment assumptions going forward.
While 2025 was a difficult year for the marketplace business, we believe the actions we took in the back half of 2025, set us up to navigate 2026 with increased visibility and confidence.
Sarah London: Finally, Medicare. Our Medicare segment delivered strong results throughout 2025. Q4 fundamental Medicare Advantage performance was in line with our expectations, setting us up with a solid jump-off point for 2026. We completed a review of our provider contract portfolio in the quarter and adjusted certain receivables accordingly, which drove the slightly elevated HBR compared to expectations. Overall, we continue to look for opportunities to position the business for improved profitability in 2026 on the way to our goal of break-even Medicare Advantage results in 2027, an important enterprise milestone. Our Medicare Advantage product positioning yielded the intended results for 2026 membership, and we expect to end Q1 with a decline in MA membership, consistent with our strategy to refine our footprint and fine-tune our value proposition for Medicaid beneficiaries.
Continued to advocate for program reform that will drive affordability, and further stabilize the individual Marketplace overall as an alternative to employer-sponsored insurance and a solution for small business owners and other hardworking Americans and their families.
Finally, Medicare.
Sarah London: Q4 fundamental Medicare Advantage performance was in line with our expectations, setting us up with a solid jump-off point for 2026. We completed a review of our provider contract portfolio in the quarter and adjusted certain receivables accordingly, which drove the slightly elevated HBR compared to expectations. Overall, we continue to look for opportunities to position the business for improved profitability in 2026 on the way to our goal of break-even Medicare Advantage results in 2027, an important enterprise milestone. Our Medicare Advantage product positioning yielded the intended results for 2026 membership, and we expect to end Q1 with a decline in MA membership, consistent with our strategy to refine our footprint and fine-tune our value proposition for Medicaid beneficiaries.
Her Medicare segment. Delivered. Strong results throughout 2025.
Fourth quarter fundamental Medicare Advantage performance was in line with our expectations, setting us up with a solid jump-off point for 2026.
We completed a review of our provider contract portfolio in the quarter and adjusted certain receivables accordingly, which drove a slightly elevated HBR compared to expectations.
Overall, we continue to look for opportunities to position the business for improved profitability in 2026 on the way to our goal of break-even Medicare Advantage results in 2027, an important milestone.
Enterprise milestone.
Sarah London: PDP ended Q4 with some additional favorability, thanks to slightly moderating trends, and that team deserves a well-earned shout-out for having managed the business expertly through significant program changes. As we look ahead to 2026, Part D enrollment is tracking to high single-digit percentage growth at the end of the first quarter compared to year-end 2025, with member mix across the products aligning well with program and formulary design. This year provides an important opportunity to build on the meaningful progress we've made in Medicare Advantage and further strengthen the platform that will most effectively serve Medicare beneficiaries as well as dual-eligible membership. We continue to focus on Stars improvement, clinical engagement, and overall SG&A efficiencies.
Sarah London: PDP ended Q4 with some additional favorability, thanks to slightly moderating trends, and that team deserves a well-earned shout-out for having managed the business expertly through significant program changes. As we look ahead to 2026, Part D enrollment is tracking to high single-digit percentage growth at the end of the first quarter compared to year-end 2025, with member mix across the products aligning well with program and formulary design. This year provides an important opportunity to build on the meaningful progress we've made in Medicare Advantage and further strengthen the platform that will most effectively serve Medicare beneficiaries as well as dual-eligible membership. We continue to focus on Stars improvement, clinical engagement, and overall SG&A efficiencies.
Our Medicare Advantage product positioning yielded, the intended results for 2026 membership. And we expect to end the first quarter with a decline in MA membership consistent with our strategy to refine our footprint and finetune our value proposition for Medicaid beneficiaries.
PDP ended Q4 with some additional favorability. Thanks to slightly moderating Trend and that to the team deserves a well-earned shout out for having managed the business. Expertly through significant program changes,
as we look ahead to 2026 Part. D enrollment is tracking to high single digit percentage growth. At the end of the first quarter compared to year, end 2025, with member mixed the products, aligning well with program and formulary design,
Opportunity to build on the meaningful progress. We've made in Medicare Advantage and further strengthen the platform that will most effectively serve Medicare beneficiaries as well as dual eligible membership.
Sarah London: At the same time, we launched a redesigned duals operating model, leveraging insights from our deep experience managing complex populations to enhance our service and member experience for a decent member base that now accounts for roughly 40% of our Medicare Advantage business. Last week's 2027 advance notice, at least initially, suggests a more pressured view of rates than industry expectations, but it does not change our focus on returning our Medicare book to profitability, aligning closely with our key Medicaid markets, and continuing to invest in quality programs and benefits that support our core member base. We expect rates to be finalized in early April, consistent with prior years. Taking a step back, our long-term goal across our businesses is to deliver industry-leading outcomes at an industry-leading cost structure.
Sarah London: At the same time, we launched a redesigned duals operating model, leveraging insights from our deep experience managing complex populations to enhance our service and member experience for a decent member base that now accounts for roughly 40% of our Medicare Advantage business. Last week's 2027 advance notice, at least initially, suggests a more pressured view of rates than industry expectations, but it does not change our focus on returning our Medicare book to profitability, aligning closely with our key Medicaid markets, and continuing to invest in quality programs and benefits that support our core member base. We expect rates to be finalized in early April, consistent with prior years. Taking a step back, our long-term goal across our businesses is to deliver industry-leading outcomes at an industry-leading cost structure.
We continue to focus on Starz Improvement, clinical engagement, and overall sgna efficiencies.
And at the same time, we launched a redesigned duals operating model, leveraging insights from our deep experience managing complex populations to enhance our service and member experience for a decent member base that now accounts for roughly 40% of our Medicare Advantage business.
Last week's 2027 advance notice at least initially suggests a more pressured view of rates than industry expectations, but it does not change our focus on returning our Medicare book to profitability, aligning closely with our key Medicaid markets, and continuing to invest in quality programs and benefits that support our core member base.
We expect rates to be finalized in early April, consistent with prior years.
Taking a step back.
Sarah London: As we create the roadmap to harvest Centene's full potential earnings power, there is no question that data, technology, and artificial intelligence will be a critical lever and accelerant to this work. Over the last few years, we have been building the necessary data foundation and systematically integrating AI into our operations, resulting in proof points around accelerated prior authorization approvals, improved call center operations, enhanced member navigation and engagement experiences, and advanced analytics capabilities that support our medical economics work and our payment integrity operations. As an example of the latter, we currently score our claims data against 75 different algorithms designed to triangulate potential fraud. Alerts are triggered and sent to a group of cross-functional experts for immediate review and intervention.
Sarah London: As we create the roadmap to harvest Centene's full potential earnings power, there is no question that data, technology, and artificial intelligence will be a critical lever and accelerant to this work. Over the last few years, we have been building the necessary data foundation and systematically integrating AI into our operations, resulting in proof points around accelerated prior authorization approvals, improved call center operations, enhanced member navigation and engagement experiences, and advanced analytics capabilities that support our medical economics work and our payment integrity operations. As an example of the latter, we currently score our claims data against 75 different algorithms designed to triangulate potential fraud. Alerts are triggered and sent to a group of cross-functional experts for immediate review and intervention.
Our long-term goal across our businesses is to deliver industry-leading outcomes at an industry-leading cost structure.
As we create the road map to harvest centene's full potential earnings power, there is no question that data technology and artificial intelligence will be a critical lever. And accelerant to this work
Sarah London: As we step into 2026, we are closely tracking the inflection of GenAI and accelerating our integration of agentic capabilities into our core operations to drive automation and efficiency, and using it as a catalyst to reimagine and elevate the experience we deliver to our members, partners, and other stakeholders. You should expect to hear more on this in the quarters ahead. 2025 challenged us, but it also made us stronger. Amid continued landscape volatility and with the benefit of enhanced visibility across lines of business as we move through the back half of the year, we took the opportunity as an organization to reassess and refresh our views of both existing and emergent headwinds and tailwinds. We have prudently positioned our 2026 outlook, incorporating an expectation that policy-related variability will continue to influence our core business lines.
Sarah London: As we step into 2026, we are closely tracking the inflection of GenAI and accelerating our integration of agentic capabilities into our core operations to drive automation and efficiency, and using it as a catalyst to reimagine and elevate the experience we deliver to our members, partners, and other stakeholders. You should expect to hear more on this in the quarters ahead. 2025 challenged us, but it also made us stronger. Amid continued landscape volatility and with the benefit of enhanced visibility across lines of business as we move through the back half of the year, we took the opportunity as an organization to reassess and refresh our views of both existing and emergent headwinds and tailwinds. We have prudently positioned our 2026 outlook, incorporating an expectation that policy-related variability will continue to influence our core business lines.
Over the last few years, we have been building the necessary data foundation and systematically integrating AI into our operations. The resulting improvements include accelerated prior authorization approvals, improved call center operations, enhanced member navigation and engagement experiences, and advanced analytics capabilities that support our medical economics work and our payment integrity operations. As an example of the latter, we currently score our claims data against 75 different algorithms designed to try and triangulate potential. Fraud alerts are triggered and sent to a group of cross-functional experts for immediate review and intervention.
As we step into 2026, we are closely tracking, the inflection of Genai and accelerating our integration of aenta capabilities into our core operations, to drive Automation and efficiency. And using it as a catalyst to reimagine and Elevate the experience. We deliver to our members partners and other stakeholders.
You should expect to hear more on this in the quarters ahead.
2025 challenged us but it also made us stronger.
Amid continued, landscape volatility, and with the benefit of enhanced visibility across lines of business. As we move through the back, half of the year. We took the opportunity as an organization to reassess and refresh our views of both existing and emergent headwinds and Tailwinds.
Sarah London: We are confident in our ability to execute against the outlook we have provided today, building on the positive momentum we have generated in recent months. And we see continued opportunity for margin expansion in the months and years ahead, while keeping our members at the center of everything we do. As I have said before, and feel only more strongly after the year we have navigated, the Centene team is an incredibly powerful engine. They are fired up and focused on the opportunity ahead and committed to the hard work necessary to deliver margin that will power our mission. With that, I will turn it over to Drew to provide more details about the quarter and our view of 2026.
Sarah London: We are confident in our ability to execute against the outlook we have provided today, building on the positive momentum we have generated in recent months. And we see continued opportunity for margin expansion in the months and years ahead, while keeping our members at the center of everything we do. As I have said before, and feel only more strongly after the year we have navigated, the Centene team is an incredibly powerful engine. They are fired up and focused on the opportunity ahead and committed to the hard work necessary to deliver margin that will power our mission. With that, I will turn it over to Drew to provide more details about the quarter and our view of 2026.
We have prudently positioned our 2026 outlook, incorporating an expectation that policy-related variability will continue to influence our core business lines.
We are confident in our ability to execute against the Outlook. We have provided today, building on the positive momentum. We have generated in recent months.
And we see continued opportunity for margin expansion in the months and years ahead, while keeping our members at the center of everything we do.
As I have said before—and feel only more strongly after the year we have navigated—the Send team is an incredibly powerful engine. They are fired up and focused on the opportunity ahead and committed to the hard work necessary to deliver margin that will power our mission.
Andrew Asher: Thank you, Sarah. Today, we reported Q4 and full-year 2025 results, including $174.6 billion in premium and service revenue and adjusted diluted earnings per share of $2.08. The Q4 GAAP diluted loss per share of $2.24 includes a $389 million net loss, prompted by a Q4 definitive agreement to divest the remaining Magellan business. Recall, we previously divested the Magellan Pharmacy and Specialty businesses at gains over the past few years. From an adjusted earnings standpoint, we are pleased that the underlying fundamentals in Q4 are tracking our prior forecasted full-year adjusted diluted EPS of greater than $2, and this sets us up well for our 2026 guidance that we'll cover in a minute... Starting with Medicaid.
Drew Asher: Thank you, Sarah. Today, we reported Q4 and full-year 2025 results, including $174.6 billion in premium and service revenue and adjusted diluted earnings per share of $2.08. The Q4 GAAP diluted loss per share of $2.24 includes a $389 million net loss, prompted by a Q4 definitive agreement to divest the remaining Magellan business. Recall, we previously divested the Magellan Pharmacy and Specialty businesses at gains over the past few years. From an adjusted earnings standpoint, we are pleased that the underlying fundamentals in Q4 are tracking our prior forecasted full-year adjusted diluted EPS of greater than $2, and this sets us up well for our 2026 guidance that we'll cover in a minute... Starting with Medicaid.
With that, I will turn it over to Drew to provide more details about the quarter and our view of 2026.
Thank you, Sarah.
Today we reported fourth quarter and full year 2025 results, including $174.6 billion in premium and service revenue and adjusted diluted earnings per share of $28. The fourth quarter GAAP diluted loss per share of $2.24 includes a $389 million net loss, prompted by a Q4 definitive agreement to divest the remaining Mellon business.
Recall, we previously discussed the Mylan, pharmacy, and specialty businesses and gains over the past few years.
From an adjusted earning standpoint. We are pleased that the underlying fundamentals in Q4 are tracking our prior forecasted full year, adjusted diluted EPS of greater than 2 dollars. And this sets us up well for our 2026 guidance, that will cover in a minute.
Andrew Asher: We saw continued progress and improvement in the HBR, with Q4 improving to 93.0%. While we have a lot further to go in Medicaid to achieve a reasonable HBR and margin, the back half of 2025 was a good start, with 2 consecutive quarters of HBR improvement. Our 1.1 net rates are supportive of our 2026 guidance of a stable Medicaid HBR, with an assumed full year 2026 net rate impact of mid-fours and a corresponding mid-fours 2026 net trend expectation. As expected, we continue to see slight attrition in membership, closing out 2025 at 12.5 million members. We continue to drive quality and affordable healthcare initiatives and work with our state partners on the optimal program structures and associated rates.
Drew Asher: We saw continued progress and improvement in the HBR, with Q4 improving to 93.0%. While we have a lot further to go in Medicaid to achieve a reasonable HBR and margin, the back half of 2025 was a good start, with 2 consecutive quarters of HBR improvement. Our 1.1 net rates are supportive of our 2026 guidance of a stable Medicaid HBR, with an assumed full year 2026 net rate impact of mid-fours and a corresponding mid-fours 2026 net trend expectation. As expected, we continue to see slight attrition in membership, closing out 2025 at 12.5 million members. We continue to drive quality and affordable healthcare initiatives and work with our state partners on the optimal program structures and associated rates.
Starting with Medicaid.
We saw continued progress and improvement in the HBR, with Q4 improving to 93.0%. While we have a lot further to go in Medicaid to achieve a reasonable HBR and margin, the back half of 2025 was a good start, with two consecutive quarters of HBR improvement.
Net Trend expectation.
Andrew Asher: While certain areas are still elevated, behavioral, home health, and high-cost drugs, we can see tangible progress in the business. Overall, this is another quarter of good progress in Medicaid. Our commercial segment HBR in Q4 was about a point higher than our forecast, with a few items moving in both directions, but the elements that matter most for 2026 were positive. Importantly, the current period medical costs and trend were slightly better than our expectations in the fourth quarter, so we feel good about Q4 fundamentals as we turn the calendar into 2026. Another positive sign in the quarter was a favorable change in our view of 2025 relative morbidity or risk adjustment based upon the third round of Wakely data. This was $200 million worth of net PNL outperformance in the quarter, which also bodes well for our 2026 pricing assumptions.
Drew Asher: While certain areas are still elevated, behavioral, home health, and high-cost drugs, we can see tangible progress in the business. Overall, this is another quarter of good progress in Medicaid. Our commercial segment HBR in Q4 was about a point higher than our forecast, with a few items moving in both directions, but the elements that matter most for 2026 were positive. Importantly, the current period medical costs and trend were slightly better than our expectations in the fourth quarter, so we feel good about Q4 fundamentals as we turn the calendar into 2026. Another positive sign in the quarter was a favorable change in our view of 2025 relative morbidity or risk adjustment based upon the third round of Wakely data. This was $200 million worth of net PNL outperformance in the quarter, which also bodes well for our 2026 pricing assumptions.
As expected, we continue to see slight attrition in membership, closing out, 2025 at 12.5 million members, we continue to drive quality and affordability Healthcare initiatives and work with our state Partners on the optimal program structures and Associated rates.
While certain areas are still elevated behavioral home health and high-cost drugs, we can see tangible progress in the business. Overall, this is another quarter of good progress in Medicaid.
Our commercial segment hbr and Q4 was about a point higher than our forecasts with a few items moving in both directions. But the elements that matter most for 2026 were positive.
Importantly, the current period medical costs and Trend were slightly better than our expectations in the fourth quarter.
So we feel good about Q4 fundamentals as we turn the calendar into 2026.
Another positive sign in the quarter was a favorable change in our view of 2025, relative morbidity or risk adjustment based upon the third round of wakeley data.
Andrew Asher: So, what more than offset this good news? Two items: a 2023 membership revenue reconciliation with CMS that has no bearing on 2026, and increases in cost and accruals related to the No Surprises Act that Sarah covered. Those two items drove the net 1% higher than planned HBR in Q4, which otherwise would have been quite favorable. Consistent with our Q3 commentary, and now bolstered by Q4 insights, we expect our marketplace pricing actions to adequately capture the 2025 and 2026 market shifts, 2026 trends, and policy changes in place during the open enrollment period, all of which support meaningful pre-tax margin expansion in 2026, compared to losing approximately 1% in 2025. In our Medicare segment, we executed well in 2025, including Q4.
Drew Asher: So, what more than offset this good news? Two items: a 2023 membership revenue reconciliation with CMS that has no bearing on 2026, and increases in cost and accruals related to the No Surprises Act that Sarah covered. Those two items drove the net 1% higher than planned HBR in Q4, which otherwise would have been quite favorable. Consistent with our Q3 commentary, and now bolstered by Q4 insights, we expect our marketplace pricing actions to adequately capture the 2025 and 2026 market shifts, 2026 trends, and policy changes in place during the open enrollment period, all of which support meaningful pre-tax margin expansion in 2026, compared to losing approximately 1% in 2025. In our Medicare segment, we executed well in 2025, including Q4.
This was a couple hundred million worth of net p&l outperformance in the quarter, which also bodes well for our 2026 pricing assumptions.
So what more than offset this Good News. 2 items, a 2023 membership, Recon Revenue reconciliation with CMS. That has no bearing on 2026.
And increases in cost and acrs related to the no surprises act, that Sarah covered.
Those two items drove the net 1% higher than planned HPR in Q4, which otherwise would have been quite favorable.
Consistent with our Q3 commentary, and now bolstered by Q4 insights, we expect our Marketplace pricing actions to adequately capture the 2025 and 2026 market shifts.
2026 Trends and policy changes in place during the open enrollment period. All of which support meaningful pre-tax, margin expansion in 2026 compared to losing approximately 1% in 2025,
Andrew Asher: In our growing PDP business, we delivered strong 2025 performance, including Q4, despite the headwinds and uncertainties created by the Inflation Reduction Act. This is a testament to our experience, cost structure, and market positioning in PDP. In our Medicare Advantage business in 2025, we progressed nicely toward our goal of break-even in 2027. Q4 fundamentals were on track, and the reported results include a write-off of some older provider receivables. As Sarah covered, we like our 2026 positioning as we wrapped up the annual enrollment period. We will provide CMS comments on the disappointing 2027 advance notice Medicare rate, which will likely cut into seniors' benefits and product selection. And as we construct the 2027 bids over the next few months, we will do so with the same goal to solve for break-even performance in 2027.
Drew Asher: In our growing PDP business, we delivered strong 2025 performance, including Q4, despite the headwinds and uncertainties created by the Inflation Reduction Act. This is a testament to our experience, cost structure, and market positioning in PDP. In our Medicare Advantage business in 2025, we progressed nicely toward our goal of break-even in 2027. Q4 fundamentals were on track, and the reported results include a write-off of some older provider receivables. As Sarah covered, we like our 2026 positioning as we wrapped up the annual enrollment period. We will provide CMS comments on the disappointing 2027 advance notice Medicare rate, which will likely cut into seniors' benefits and product selection. And as we construct the 2027 bids over the next few months, we will do so with the same goal to solve for break-even performance in 2027.
In our Medicare segment, we executed well in 2025, including the fourth quarter, in our growing PDP business. We delivered strong 2025 performance, including Q4, despite the headwinds and uncertainties created by the Inflation Reduction Act.
This is a testament to our experience cost structure and Market positioning in PDP.
In our Medicare Advantage business, in 2025, we progressed nicely toward our goal of break even in 2027.
Q4 fundamentals were on track and the reported results. Include a write-off of some older provider receivables.
As Sarah covered we'd, like our 2026 positioning as we wrapped up the annual enrollment period.
We will provide CMS comments on the disappointing 2027 Advance Notice Medicare rate, which will likely cut into seniors' benefits and product selection.
And as we construct, the 2027, bids over the next few months, we will do. So with the same goal to solve for Break Even performance in 2027,
Andrew Asher: Our Q4 adjusted SG&A expense ratio of 7.5% brings our full year to 7.4%, which is 110 basis points lower than 2024, reflecting continued discipline and scale. We ended the year with about $400 million of cash available for general corporate use. We reduced debt by $189 million in the quarter and ended up with a debt-to-cap ratio of 46.5%. Our medical claims liability totaled $20.5 billion and represents 46 days in claims payable, a decrease of 2 days as compared to Q3 of 2025, driven by payouts of state-directed payments and the elimination of the Medicare premium deficiency reserve in Q4, which is corroboration of the progress we are making in Medicare Advantage for 2026.
Drew Asher: Our Q4 adjusted SG&A expense ratio of 7.5% brings our full year to 7.4%, which is 110 basis points lower than 2024, reflecting continued discipline and scale. We ended the year with about $400 million of cash available for general corporate use. We reduced debt by $189 million in the quarter and ended up with a debt-to-cap ratio of 46.5%. Our medical claims liability totaled $20.5 billion and represents 46 days in claims payable, a decrease of 2 days as compared to Q3 of 2025, driven by payouts of state-directed payments and the elimination of the Medicare premium deficiency reserve in Q4, which is corroboration of the progress we are making in Medicare Advantage for 2026.
Our Q4 adjusted sgna expense ratio of 7.5%, brings our full year to 7.4%, which is 110 basis points. Lower than 2024, reflecting continued, discipline and scale.
We ended the year with about $400 million of cash available for general corporate use. We reduced debt by $189 million in the quarter and ended up with a debt-to-cap ratio of 46 and a half percent.
Our medical claims liability totaled $20.5 billion and represents 46 days in claims payable, a decrease of 2 days as compared to the third quarter of 2025.
Andrew Asher: That's a wrap on 2025, a strong finish to a rough year. Let's move to 2026 and associated guidance elements, including a few slides we posted on our website. We expect premium and service revenue of $170 to $174 billion. As you can see in the bridge, Medicaid premium revenue is down a couple billion, including some member attrition in 2026, partially offset by rate increases. We expect Medicaid member months down 5% to 6% in 2026. We expect marketplace revenue to be down about $8 billion, driven by policy and market impacts, including the expiration of the enhanced APTCs, net of rate increases designed to increase yield and improve margin.
Drew Asher: That's a wrap on 2025, a strong finish to a rough year. Let's move to 2026 and associated guidance elements, including a few slides we posted on our website. We expect premium and service revenue of $170 to $174 billion. As you can see in the bridge, Medicaid premium revenue is down a couple billion, including some member attrition in 2026, partially offset by rate increases. We expect Medicaid member months down 5% to 6% in 2026. We expect marketplace revenue to be down about $8 billion, driven by policy and market impacts, including the expiration of the enhanced APTCs, net of rate increases designed to increase yield and improve margin.
driven by payouts of State directed payments and the elimination of the Medicare premium deficiency. Reserve in Q4, which is corroboration of the progress, we are making in Medicare Advantage for 2026.
That's a wrap on 2025 a strong finish to a rough year.
Let's move to 2026 and associated guidance, elements, including a few slides we posted on our website.
We expect premium and service revenue of $170 to $174 billion, as you can see in the bridge. Medicaid premium revenue is down a couple of billion, including some member attrition in 2026, partially offset by rate increases.
We expect Medicaid member months down 5 to 6% in 2026.
Andrew Asher: To give you some membership magnitude, as Sarah outlined, we expect around 3.5 million marketplace members as of the end of Q1 and slight attrition thereafter, though we are still in the payment grace periods, which could swing membership somewhat during Q1. We expect the Medicare segment to grow premium revenue approximately $7.5 billion, driven by our Medicare PDP business, the majority of which is from the premium yield increase, which we'll touch on in a moment. Coupled with growth in membership, which sits at about 8.7 million coming out of open enrollment. Medicare Advantage revenue is projected to be essentially flat from 2025 to 2026, with membership down intentionally and yields up. The forecasted 2026 revenue split in the Medicare segment is approximately 41% Medicare Advantage and 59% PDP.
Drew Asher: To give you some membership magnitude, as Sarah outlined, we expect around 3.5 million marketplace members as of the end of Q1 and slight attrition thereafter, though we are still in the payment grace periods, which could swing membership somewhat during Q1. We expect the Medicare segment to grow premium revenue approximately $7.5 billion, driven by our Medicare PDP business, the majority of which is from the premium yield increase, which we'll touch on in a moment. Coupled with growth in membership, which sits at about 8.7 million coming out of open enrollment. Medicare Advantage revenue is projected to be essentially flat from 2025 to 2026, with membership down intentionally and yields up. The forecasted 2026 revenue split in the Medicare segment is approximately 41% Medicare Advantage and 59% PDP.
Place revenue to be down to about $8 billion, driven by policy and market impacts, including the expiration of the enhanced APCs. Net of rate increases designed to increase yield and improve margin.
To give you some membership, magnitude, as South as Sarah outlined. We expect around 3 and a half million Marketplace members as of the end of q1 and slight attrition thereafter.
Though, we are still in the payment Grace periods, which could swing membership somewhere, during q1.
We expect the Medicare segment to grow premium revenue by approximately $7.5 billion, driven by our Medicare PDP business. The majority of this growth is from the premium yield increase, which we will touch on in a moment.
coupled with growth in membership, which sits at about 8.7 million coming out of open enrollment,
Medicare Advantage. Revenue is projected to be essentially, flat from 25 to 26, with membership down intentionally and yields up.
The forecast for 2026 revenue split in the Medicare segment is approximately 41% Medicare Advantage and 59% PDP.
Andrew Asher: We expect a consolidated HBR of 90.9% to 91.7% in 2026, at the midpoint, down 60 basis points from 2025. That's driven by an expected recovery in Marketplace, as you can see in the bridge. Consistent with previous commentary, we initially expect a flat Medicaid segment HBR in 2026 compared to 2025's 93.7%. And in the Medicare segment, we expect improvement in the Medicare Advantage and a higher PDP HBR, driven by two things. One, we are initially assuming a 2026 pretax margin around 2%, down from a good year in the 3s. And two, there was a meaningful increase in the direct subsidy from $143 to $200, reflecting industry pricing for higher pharmacy trends due to the IRA.
Drew Asher: We expect a consolidated HBR of 90.9% to 91.7% in 2026, at the midpoint, down 60 basis points from 2025. That's driven by an expected recovery in Marketplace, as you can see in the bridge. Consistent with previous commentary, we initially expect a flat Medicaid segment HBR in 2026 compared to 2025's 93.7%. And in the Medicare segment, we expect improvement in the Medicare Advantage and a higher PDP HBR, driven by two things. One, we are initially assuming a 2026 pretax margin around 2%, down from a good year in the 3s. And two, there was a meaningful increase in the direct subsidy from $143 to $200, reflecting industry pricing for higher pharmacy trends due to the IRA.
We expect a Consolidated HPR of 90.9 to 91.7% in 2026 at the midpoint down 60 basis points from 2025.
That's driven by an expected recovery in Marketplace, as you can see in the bridge.
Consistent with previous commentary, we initially expect a flat Medicaid segment HBR in 2026 compared to 2025—93.7 percent.
And in the Medicare segment, we expect Improvement in the Medicare Advantage and a higher PDP hbr driven by 2 things.
Andrew Asher: So think about a rise in premium and pharmacy expense without any need to increase SG&A. This drives a higher mathematical HBR. That's factored into our initial 2% pretax margin forecast for PDP. You can see the other guidance elements, including stability in the SG&A rate, continued paydown of debt, and associated impact on interest expense, reduced investment income from assumed Fed Fund rate cuts, an adjusted tax rate of 26% to 27%, slightly higher than a normal statutory rate, given the mix and level of earnings forecasted for 2026. No share buyback reflected in guidance. We will continue to assess the field of capital deployment opportunities as we generate excess cash.
Drew Asher: So think about a rise in premium and pharmacy expense without any need to increase SG&A. This drives a higher mathematical HBR. That's factored into our initial 2% pretax margin forecast for PDP. You can see the other guidance elements, including stability in the SG&A rate, continued paydown of debt, and associated impact on interest expense, reduced investment income from assumed Fed Fund rate cuts, an adjusted tax rate of 26% to 27%, slightly higher than a normal statutory rate, given the mix and level of earnings forecasted for 2026. No share buyback reflected in guidance. We will continue to assess the field of capital deployment opportunities as we generate excess cash.
And two, there was a meaningful increase in the direct subsidy from $143 to $200, reflecting industry pricing for higher pharmacy trends due to the IRA.
So think about a rise in premium and Pharmacy expense, without any need to increase sgna this drives a higher mathematical hbr. That's factored into our initial 2% pre-tax, margin forecast for PDP
You can see the other guidance elements including stability in the sgna rate. Continued pay down of debt and Associated impact on interest expense.
Reduced investment income from assumed fed fund rate cuts.
And adjusted tax rate of 26% to 27% slightly higher than a normal statutory rate, given the mix and level of earnings forecasted for 2026.
Andrew Asher: With respect to seasonality of earnings, as we sit here today, we expect the majority of 2026 adjusted EPS in Q1, stepping down in Q2, and further to around breakeven in Q3 with a loss in Q4. This is driven by the seasonality and benefit design of Marketplace and PDP products, both with lower HBRs in the beginning of the year and higher at the end of the year. Our EPS outlook of greater than $3 reflects a meaningful forecasted turnaround of marketplace margins, Medicaid stabilization, continued Medicare Advantage progress, a prudent PDP margin assumption, and lower interest expense from continued deleveraging. I'm sure you are too, but we are pleased to turn the page on 2025, with 2026, one step towards restoration of earnings for Centene. Thank you for your interest in Centene, and Rocco, please open it up for questions.
Drew Asher: With respect to seasonality of earnings, as we sit here today, we expect the majority of 2026 adjusted EPS in Q1, stepping down in Q2, and further to around breakeven in Q3 with a loss in Q4. This is driven by the seasonality and benefit design of Marketplace and PDP products, both with lower HBRs in the beginning of the year and higher at the end of the year. Our EPS outlook of greater than $3 reflects a meaningful forecasted turnaround of marketplace margins, Medicaid stabilization, continued Medicare Advantage progress, a prudent PDP margin assumption, and lower interest expense from continued deleveraging. I'm sure you are too, but we are pleased to turn the page on 2025, with 2026, one step towards restoration of earnings for Centene. Thank you for your interest in Centene, and Rocco, please open it up for questions.
No share buyback. Reflected in guidance, we will continue to assess the field of capital deployment opportunities. As we generate excess cash.
With respect to seasonality of earnings. As we sit here today, we expect the majority of 2026, adjusted EPS, in q1 stepping down in Q2, and further, to around break, even in Q3 with a loss. In Q4, this is driven by the seasonality and benefit design of marketplace and PDP products, both with lower hbrs in the beginning of the year and higher, at the end of the year.
Our EPS outlook of greater than $3 reflects a meaningful forecast to turn around marketplace margins.
Medicaid stabilization continued. Medicare Advantage progress—a prudent PDP margin assumption—and lower interest expense from continued deleveraging.
I'm sure you are too but we are pleased to turn the page on 2025 with 2026 1, step towards restoration of earnings for centene.
Operator: Thank you. We will now begin the question and answer session. To ask a question, you may press star then one on your telephone keypad. If you are using a speakerphone, we ask that you please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then two. We do ask that you please limit yourselves to one question at a time. At this time, we'll pause for just a moment to assemble our roster. Today's first question comes from Ann Hynes at Mizuho. Please go ahead.
Operator: Thank you. We will now begin the question and answer session. To ask a question, you may press star then one on your telephone keypad. If you are using a speakerphone, we ask that you please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then two. We do ask that you please limit yourselves to one question at a time. At this time, we'll pause for just a moment to assemble our roster. Today's first question comes from Ann Hynes at Mizuho. Please go ahead.
Thank you for your interest in centene and rockco, please open it up for questions.
Thank you. We will now begin the question and answer session.
To ask a question. You may press star 1 on your telephone keypad.
If you are using the speakerphone, we ask that you please pick up your handset before pressing the keys.
If at any time your question has been addressed, do you like to enjoy your question? Please press star 2.
We do ask you, please let ourselves to 1 question at a time.
At this time, we'll pause for just a moment to assemble our roster.
Ann Hynes: Great, thanks. On your rate expectation for Medicaid for 4.5%, I would think that would be higher, just given trend has been so elevated over the past couple of years. Can you just give us more details what's happening on the state level, and do you view that as conservative? Would you be able to get some mid-year rate increases? Any color would be great. Thank you.
Ann Hynes: Great, thanks. On your rate expectation for Medicaid for 4.5%, I would think that would be higher, just given trend has been so elevated over the past couple of years. Can you just give us more details what's happening on the state level, and do you view that as conservative? Would you be able to get some mid-year rate increases? Any color would be great. Thank you.
And today's first question comes from an Hinds at mizuko. Please go ahead.
Sarah London: Sure. Thanks, Anne, for the question. So a couple of things. One, as we said throughout 2025, the conversation with our state partners continue to be constructive. I think we also have the benefit of the fact that as we step into this rate cycle, we have a full two years of both the acuity dynamics and the step up in trend encapsulated in the data, and so we think that is important and helpful to inform rate decisions. So again, we're starting with a prudent assumption around that 4.5% for 2026. I would point to the fact that our 2025 rates matured favorably from where we started at the beginning of 2025 and ended with that composite rate at, you know, roughly 5.5%.
Sarah London: Sure. Thanks, Anne, for the question. So a couple of things. One, as we said throughout 2025, the conversation with our state partners continue to be constructive. I think we also have the benefit of the fact that as we step into this rate cycle, we have a full two years of both the acuity dynamics and the step up in trend encapsulated in the data, and so we think that is important and helpful to inform rate decisions. So again, we're starting with a prudent assumption around that 4.5% for 2026. I would point to the fact that our 2025 rates matured favorably from where we started at the beginning of 2025 and ended with that composite rate at, you know, roughly 5.5%.
Um, would you be able to get the midyear, um, rate increases? Any color would be great. Thank you.
Thank you for the question. Um, so—
Sarah London: And then balanced against that, obviously, is all of the work that we've done over the back half of 2025 to really bend trend, which is what's driving the assumption of the flat HBR year over year.
Sarah London: And then balanced against that, obviously, is all of the work that we've done over the back half of 2025 to really bend trend, which is what's driving the assumption of the flat HBR year over year.
On as we've said, throughout 2025 the conversation, with our state Partners continue to be constructive. I think we also have the benefit of the fact that, as we step into this rate cycle, we have a full 2 years of both the Acuity Dynamics and the Step Up in Trend, encapsulated in the data. And so we think that is important and helpful to inform rate decisions. Um, so again, we're starting with The Prudent assumption around that 4 and a half percent for 2026. I would point to the fact that our 2025 rates matured favorably from where we started at the beginning of 2025 and ended with that composite rate at, you know, roughly 5 and a half percent. Um, and then balanced against that, obviously, is all of the work that we've done over the back half of 25 to really Bend Trend, which is, what's driving the Assumption of the flat hbr year-over-year.
Operator: Thank you. Our next question today comes from Justin Lake of Wolfe Research. Please go ahead.
Operator: Thank you. Our next question today comes from Justin Lake of Wolfe Research. Please go ahead.
Percent you today I was wondering just to make a whole research. Please go ahead.
Andrew Asher: Thanks. Wanted to kind of follow up on Anne's question here. First, you, you talked about trend and 4.5% in 2026 for Medicaid. Curious what that trend was in 2025, and maybe you can help us understand first half versus second half, just to get the run rate kind of coming out of the year versus that 4.5% assumption next year. And then, you know, to Anne's question on the rates.
Justin Lake [Analyst: Thanks. Wanted to kind of follow up on Anne's question here. First, you, you talked about trend and 4.5% in 2026 for Medicaid. Curious what that trend was in 2025, and maybe you can help us understand first half versus second half, just to get the run rate kind of coming out of the year versus that 4.5% assumption next year. And then, you know, to Anne's question on the rates.
Justin Lake: ... Your rates were 5.5 last year. Your rates are 4.5% this year. I'm just curious, how do states justify that, given, you know, when you have your conversations with them, given what's going on in the market, what's going on with trend and acuity, et cetera? And maybe you could just tell us how Q1 looks versus the 4.5 full year. Thanks.
Justin Lake [Analyst: ... Your rates were 5.5 last year. Your rates are 4.5% this year. I'm just curious, how do states justify that, given, you know, when you have your conversations with them, given what's going on in the market, what's going on with trend and acuity, et cetera? And maybe you could just tell us how Q1 looks versus the 4.5 full year. Thanks.
Thanks. I wanted to kind of follow up on Ann's question here. First, you know, you talked about Trend and uh, 4 and a half percent in 2026 for Medicaid, curious. What that Trend was in 2025 and maybe you can help us understand first half versus second half just to get the Run rate, kind of coming out of the Year versus that 4 and a half percent assumption next year. And then, you know, to answer question on the race.
Your your rates were 5 and a half. Last year, your rates are 4 and a half percent this year.
Sarah London: Sure. Lots of pieces there. So, 91 rates were consistent with expectations. Let's go back to trend. So, 2025 trend was in that mid sixes, which I think we talked about on the Q3 call. And then the view of 2026 around mid fours is really a net trend assumption. And so again, important to think about the fact that we are jumping off of an elevated baseline that included that 94.9 in Q2, and all of the aggressive action that we took in the back half of the year, obviously coming through Q4 with a 93.0.
Sarah London: Sure. Lots of pieces there. So, 91 rates were consistent with expectations. Let's go back to trend. So, 2025 trend was in that mid sixes, which I think we talked about on the Q3 call. And then the view of 2026 around mid fours is really a net trend assumption. And so again, important to think about the fact that we are jumping off of an elevated baseline that included that 94.9 in Q2, and all of the aggressive action that we took in the back half of the year, obviously coming through Q4 with a 93.0.
I'm just curious how the stage justify that given, you know, when you have your conversations with them, given what's going on in the market? What's going on with Trend and Acuity, Etc? And maybe you could just tell us how 1 1 looks versus the 4 and a half billion year. Thanks.
Sarah London: So equally important is sort of the assumption around the proof points that we have in terms of bending trend in the back half of the year, as well as bankable proof points around actions that we took in Q3 and Q4 that don't take effect until 2026. So that's part of what gives us a view of sort of that mid-fours net trend assumption. And then relative to rates, to your point, we ended the year with that composite of 5.5. We started the year lower than that. So believe that we've sort of taken a prudent view of rates in the mid-fours for 2026, and we'll continue to, you know, work with the states as we have all along, to make sure that they have the most recent trend data.
Sarah London: So equally important is sort of the assumption around the proof points that we have in terms of bending trend in the back half of the year, as well as bankable proof points around actions that we took in Q3 and Q4 that don't take effect until 2026. So that's part of what gives us a view of sort of that mid-fours net trend assumption. And then relative to rates, to your point, we ended the year with that composite of 5.5. We started the year lower than that. So believe that we've sort of taken a prudent view of rates in the mid-fours for 2026, and we'll continue to, you know, work with the states as we have all along, to make sure that they have the most recent trend data.
Sure, um, lots of pieces there. So, so, uh, 1, 1, 1 rates were consistent with expectations. Um, let's go back to Trends. So, uh, 2025 Trend was in that mid 6s, um, which I think we, we talked about on the Q3 call, um, and then the view of 2026 around. Mid 400s is really a net Trend assumption. Um, and so again, important to think about the fact that we are jumping off of an elevated Baseline that included that 949 in Q2, um, and all of the aggressive action that we took in the back half of the Year obviously coming through Q4 with a 9330,
Um, so equally important is sort of the Assumption around the proof points that we have in terms of bending Trend in the back half of the year as well as bankable proof points around actions that we took in Q3 and Q4 that don't take effect until 2026. So that's part of what gives us a view of sort of that mid fours, net Trend, assumption and then relative to rates
Sarah London: Again, we have the benefit of that sort of trailing two years now, which we've been working our way up to. And then, you know, also talking to states about places where, in the absence of feeling like they can push rate, they can also make program changes. And we've called out a number of those, but if I just think about the back half of 2025, we have proof points around states carving out high-cost drugs. They have clipped ABA outlier providers who, you know, who are overbilling. We've seen PBM control and formulary control sort of shift further back to us, guardrails around CCBHCs. So lots of, I think, thoughtful program decisions that are sort of a proxy for addressing trend without having to do it explicitly through rate.
Sarah London: Again, we have the benefit of that sort of trailing two years now, which we've been working our way up to. And then, you know, also talking to states about places where, in the absence of feeling like they can push rate, they can also make program changes. And we've called out a number of those, but if I just think about the back half of 2025, we have proof points around states carving out high-cost drugs. They have clipped ABA outlier providers who, you know, who are overbilling. We've seen PBM control and formulary control sort of shift further back to us, guardrails around CCBHCs. So lots of, I think, thoughtful program decisions that are sort of a proxy for addressing trend without having to do it explicitly through rate.
Um, to your point, we ended the year with that composite of 5 and a half, we started the year lower than that. So believe that we sort of take, in a prudent view of rates in the mid fours for 2026 and we'll continue to, you know, work with the states as we have all along to make sure that they have the most recent Trend data. Again, a full, we have the benefit of that sort of trailing 2 years now, which we've been working our way up to. Um, and then, you know, also talking to States about places, where in the absence of feeling, like they can push rate, they can also make program changes and we've called out a number of those, but if I just think about the back half of 2025, we have proof points around States carving out high-cost drugs, they have clipped, um, Abba, outlier, um, providers, who you know who are over billing. We've seen PBM control and formulary control sort of shift further back to us. Guard rails around ccbhc. Um, so lots of I think thoughtful program decisions.
Sarah London: So just net-net, you know, we're obviously calling for a flat HBR year-over-year. And I will say, as I have said before, if that is all we deliver, I will be very disappointed, and I know the team will, too.
Sarah London: So just net-net, you know, we're obviously calling for a flat HBR year-over-year. And I will say, as I have said before, if that is all we deliver, I will be very disappointed, and I know the team will, too.
That are sort of a proxy for addressing, um, trend without having to do it explicitly through rate. So, just net-net, you know, we're obviously calling for a flat HBR year-over-year, and I will say, as I have said before, if that is all we deliver, I will be very disappointed, and I know the team will too.
Operator: Thank you. Our next question today comes from Kevin Fischbeck with BIA. Please go ahead.
Operator: Thank you. Our next question today comes from Kevin Fischbeck with BIA. Please go ahead.
Thank you. And our next question today—I was trying with Kevin Fischbeck with BofA. Please go ahead.
Kevin Fischbeck: Great, thanks. I guess, moving to the exchanges, can you talk a little bit about, you know, the confidence and the visibility? Obviously, the exchange members have changed dramatically. You gave a little bit of color there, but I guess in particular, you know, you talked about the metal shift, tier shifting. I kind of remember Bronze not being a great plan historically, and now it seems to be growing overall. So I just wanna make sure that, you know, we're not gonna be caught off guard by this, you know, metal tier shift that you're gonna be seeing next year. And any other additional color you can give about why you feel comfortable in margin improvement on exchanges this year? Thanks.
Kevin Fischbeck: Great, thanks. I guess, moving to the exchanges, can you talk a little bit about, you know, the confidence and the visibility? Obviously, the exchange members have changed dramatically. You gave a little bit of color there, but I guess in particular, you know, you talked about the metal shift, tier shifting. I kind of remember Bronze not being a great plan historically, and now it seems to be growing overall. So I just wanna make sure that, you know, we're not gonna be caught off guard by this, you know, metal tier shift that you're gonna be seeing next year. And any other additional color you can give about why you feel comfortable in margin improvement on exchanges this year? Thanks.
Great, thanks. Um,
Sarah London: Yeah, thanks, Kevin. So let's go all the way back to Q3, as we kind of read and reacted to the 2025 weekly data and a much improved visibility over the baseline morbidity that we would be carrying into 2026. You know, just an incredible execution by the team, demonstrating agility and depth of expertise to reprice and reposition the, you know, the entirety of the book in that short period of time. And taking into account, again, the baseline morbidity trend assumptions, the risk pool impacts of both 2025 and anticipated 2026 program integrity measures, as well as the expiration of the enhanced APTCs, all of which netted out to that mid-30s% rate, you know, pricing increase for 2026.
Sarah London: Yeah, thanks, Kevin. So let's go all the way back to Q3, as we kind of read and reacted to the 2025 weekly data and a much improved visibility over the baseline morbidity that we would be carrying into 2026. You know, just an incredible execution by the team, demonstrating agility and depth of expertise to reprice and reposition the, you know, the entirety of the book in that short period of time. And taking into account, again, the baseline morbidity trend assumptions, the risk pool impacts of both 2025 and anticipated 2026 program integrity measures, as well as the expiration of the enhanced APTCs, all of which netted out to that mid-30s% rate, you know, pricing increase for 2026.
Kind of remember bronze not being a great plan historically. Um, and and now it seems to be growing overall. So I just want to make sure that um, you know, we're not going to be caught off sides by this uh you know, metal tier ship that you're going to be seeing next year. Um, and then any other additional colors you have about why you feel comfortable and margin Improvement on exchanges this year, thanks?
Yeah, thanks, Kevin. Um, so
Sarah London: So part of the confidence comes from, I think, the work that we did, and sort of the assumptions that we made coming into the year. Then, as we stepped into open enrollment, really watching membership progress, through kind of effectuation and down into paid membership. Where we sit here today in early February, we actually have a very good view of sort of that paid membership base, and given our history, a view of how that paid membership matures through the, you know, February, March timeframe, where there's still a little bit of administrative, opportunity and sort of grace period to get worked out, and that's where we get to that 3.5 million member estimate by the end of Q1.
Sarah London: So part of the confidence comes from, I think, the work that we did, and sort of the assumptions that we made coming into the year. Then, as we stepped into open enrollment, really watching membership progress, through kind of effectuation and down into paid membership. Where we sit here today in early February, we actually have a very good view of sort of that paid membership base, and given our history, a view of how that paid membership matures through the, you know, February, March timeframe, where there's still a little bit of administrative, opportunity and sort of grace period to get worked out, and that's where we get to that 3.5 million member estimate by the end of Q1.
Um, as we kind of read and reacted to the 2025 weekly data and a much improved visibility over the Baseline morbidity, that we would be carrying into 2026 and, you know, just a incredible execution by the team demonstrating agility and depth of expertise to reprice and reposition the, you know, the entirety of the book. Um, in that short period of time and taking into account. Again, the Baseline morbidity um, Trend assumptions, the risk pool impacts of both 2025 and anticipated 2026 program, Integrity measures, as well as the expiration of the enhanced apcs, all of which netted out to that mid-30s percent, um, rate, you know, pricing increase for 2026. So, part of the confidence comes from. I think the work that we did, um, and sort of the assumptions that we made coming into the year, then as we stepped into open enrollment really watching membership progress um through kind of effectual.
Sarah London: So I feel like standing here where we are today, feel like we have pretty good visibility into how open enrollment played out, and then we'll, you know, the tail of that will continue to shake out. To your point, the distribution of metal tiers is different this year than in past years. So we're a little over 30%, in bronze, which is up from that 19% to 24% range we talked about in past years. We do see stability in sort of core demographics around gender distribution and average age, has not changed. And then to your question about how bronze has, has operated historically, the bronze products operated differently pre-EAPTCs than they did during the EAPTC period.
Sarah London: So I feel like standing here where we are today, feel like we have pretty good visibility into how open enrollment played out, and then we'll, you know, the tail of that will continue to shake out. To your point, the distribution of metal tiers is different this year than in past years. So we're a little over 30%, in bronze, which is up from that 19% to 24% range we talked about in past years. We do see stability in sort of core demographics around gender distribution and average age, has not changed. And then to your question about how bronze has, has operated historically, the bronze products operated differently pre-EAPTCs than they did during the EAPTC period.
Situation and down into paid membership where we sit here today in early February. We actually have a very good view of sort of that paid membership base and given our history of view of how that paid membership matures through the, you know, February March time frame, where there's still a little bit of administrative, um, opportunity and sort of grace period to get worked out. And that's where we get to that 3.5 million, uh, member estimate by the end of q1. So feel like standing here where we are today, feel like we have, um, pretty good. Visibility into how open enrollment played out. And then we'll, you know, the tale of that will continue to shake out to your point. The distribution of metal tiers is
Sarah London: And again, one of the benefits of having been in the market for as long as we have is that we have all of that data, and we had all of that data back in Q3 when we went through and re-underwrote all of our assumptions relative to 2026. We did that across metal tiers, and we're thoughtful about what the impact, what might be. And I think what you would see year-over-year is also sort of a reduction in the footprint where we are a low-cost Bronze player. So, you know, again, just trying to leverage not just the increased visibility that we had from the data, but just the depth of experience and data we have from sort of end-to-end, the tenure of the program, to give us a view of where we're sitting today.
Sarah London: And again, one of the benefits of having been in the market for as long as we have is that we have all of that data, and we had all of that data back in Q3 when we went through and re-underwrote all of our assumptions relative to 2026. We did that across metal tiers, and we're thoughtful about what the impact, what might be. And I think what you would see year-over-year is also sort of a reduction in the footprint where we are a low-cost Bronze player. So, you know, again, just trying to leverage not just the increased visibility that we had from the data, but just the depth of experience and data we have from sort of end-to-end, the tenure of the program, to give us a view of where we're sitting today.
Sarah London: Also, I would just add, have the benefit of, you know, having set 2026 guidance with full visibility into how 2025 and the vast majority of open enrollment played out. So all of that goes into why we feel confident that we will be able to deliver meaningful margin improvement in this business in 2026.
Sarah London: Also, I would just add, have the benefit of, you know, having set 2026 guidance with full visibility into how 2025 and the vast majority of open enrollment played out. So all of that goes into why we feel confident that we will be able to deliver meaningful margin improvement in this business in 2026.
Soft metal tiers, and we were thoughtful about, um, what the impact might be. And I think what you would see year-over-year is also sort of a reduction in the footprint where we are a low-cost bronze player. So, um, you know, again, just trying to leverage not just the increased visibility that we had from the data but just the depth of experience and data we have from, um, sort of end-to-end, the tenure of the program to give us a view of where we're sitting today. And also, I would just add, have the benefit of, you know, having set 2026 guidance, um, with full visibility into how 2025 and the vast majority of open enrollment played out. So all of that goes into why we feel confident that we will be able to deliver meaningful margin improvement in this business in 2026.
Operator: Thank you. Our next question today comes from Stephen Baxter at Wells Fargo. Please go ahead.
Operator: Thank you. Our next question today comes from Stephen Baxter at Wells Fargo. Please go ahead.
Stephen Baxter: Yeah. Hi, thanks. I wanted to come back to the, the Medicaid moving pieces. I guess I'd just love a little bit better of a sense of maybe how much incremental decline in membership. I think the membership months were guided down 5% or 6%, but I think a good deal of that would be explained by basically what you saw in 2025. And as we think about the acuity impact, to the extent that you continue to see disenrollment at pace closer to what you saw this past quarter, so down, like, 1.5%, does that place any weight on the acuity assumptions that you had during the guidance at this point in time? Thanks.
Stephen Baxter: Yeah. Hi, thanks. I wanted to come back to the, the Medicaid moving pieces. I guess I'd just love a little bit better of a sense of maybe how much incremental decline in membership. I think the membership months were guided down 5% or 6%, but I think a good deal of that would be explained by basically what you saw in 2025. And as we think about the acuity impact, to the extent that you continue to see disenrollment at pace closer to what you saw this past quarter, so down, like, 1.5%, does that place any weight on the acuity assumptions that you had during the guidance at this point in time? Thanks.
Thank you. Our next question today comes from Stephen Baxter with Wells Fargo. Please go ahead.
Yeah. Hi thanks. Uh, I wanted to come back to the the Medicaid moving pieces, I guess we just love a little bit better of a sense of maybe how much incremental decline in membership. I think the membership months were guided down 5 or 6%, but I think a good deal of that would be explained by basically what you saw in 2025 and as we think about the Acuity impact, um, to the extent that you continue to see disenrollment at PACE, closer to what you saw this past quarter, so down like a percent and a half. Is that place any weight on the Acuity assumptions that you
Sarah London: Yeah. Thanks, Stephen. I'll hit this at a high level and then ask Drew to add any color. So what we talked about member months, we talked about slight attrition in Q1, that there was an assumption for continued attrition consistent with what we've seen, for example, through 2025, in terms of states tightening the eligibility and reverification process coming out of COVID. And then we also have a couple of program changes that we know about, including, for example, the Florida CMS program rolling off 1 October 2024, as well as sort of a probability weighted bucket of member puts and takes that we track state by state.
Sarah London: Yeah. Thanks, Stephen. I'll hit this at a high level and then ask Drew to add any color. So what we talked about member months, we talked about slight attrition in Q1, that there was an assumption for continued attrition consistent with what we've seen, for example, through 2025, in terms of states tightening the eligibility and reverification process coming out of COVID. And then we also have a couple of program changes that we know about, including, for example, the Florida CMS program rolling off 1 October 2024, as well as sort of a probability weighted bucket of member puts and takes that we track state by state.
I think the guidance at this point in time, thanks.
Sarah London: you know, I think if you were to unpack that, you would find that we're pretty prudent in our assumptions around membership there, with an eye to what the additional acuity impact might be, and all of that is sort of considered in guidance. But Drew, I don't know if there's any other additional pieces you wanna call out.
Sarah London: you know, I think if you were to unpack that, you would find that we're pretty prudent in our assumptions around membership there, with an eye to what the additional acuity impact might be, and all of that is sort of considered in guidance. But Drew, I don't know if there's any other additional pieces you wanna call out.
Andrew Asher: Yeah, right. You mentioned, Stephen, the 5 to 6% member months reduction through the year. The full year would be higher than that in terms of the membership attrition. I think about it in two buckets, as Sarah indicated. One would be sort of a, you know, maybe a little over a point per quarter of continued attrition, and we saw that basically throughout 2025. Then the Children's Medical Services business that we expect to roll off October 1, and then, as Sarah mentioned, sort of a pool of other sort of RFP-related probability weighted membership items.
Drew Asher: Yeah, right. You mentioned, Stephen, the 5 to 6% member months reduction through the year. The full year would be higher than that in terms of the membership attrition. I think about it in two buckets, as Sarah indicated. One would be sort of a, you know, maybe a little over a point per quarter of continued attrition, and we saw that basically throughout 2025. Then the Children's Medical Services business that we expect to roll off October 1, and then, as Sarah mentioned, sort of a pool of other sort of RFP-related probability weighted membership items.
Andrew Asher: The only other thing to think about is there's very few impacts of OB3 in terms of membership in 2026, but one of those is, I think around Q1, that a subset of the New York Essential Plan will be rolling off, you know, due to sort of an OB3 provision. That's about 140,000 or so members for us. So that's also in the $88 billion midpoint of guidance, the 5% to 6% member months reduction, and the little bit higher than that full year absolute membership attrition.
Drew Asher: The only other thing to think about is there's very few impacts of OB3 in terms of membership in 2026, but one of those is, I think around Q1, that a subset of the New York Essential Plan will be rolling off, you know, due to sort of an OB3 provision. That's about 140,000 or so members for us. So that's also in the $88 billion midpoint of guidance, the 5% to 6% member months reduction, and the little bit higher than that full year absolute membership attrition.
Medical Services, uh, business that we expect to, uh, roll off 101. And then, as Sarah mentioned, sort of a pool of other, uh, sort of RFP-related, um, probability-weighted, uh, membership items. The only other thing to think about is there's very few impacts of OB3 in terms of membership in 2026, but one of those is, uh, I think around 71, a subset of the New York...
Central plan will be rolling off, you know, due to sort of an OB3 provision. That's about 140,000 or so members for us. So, that's also in the
$88 billion midpoint of guidance, the 5 to 6% member months reduction, and the little bit higher than that for the full year.
Absolute membership, attrition.
Operator: Thank you. Our next question today comes from Sarah James at Cantor. Please go ahead.
Operator: Thank you. Our next question today comes from Sarah James at Cantor. Please go ahead.
Sarah James: Thank you. Can you help us understand the mechanics of the actuarial soundness look-back process? Like, how far back are they looking now? How long of a lag does that typically take to come to an agreement on what trends actually were? And as we move forward into continued periods of disruption through work requirements or additional redeterminations, how are you thinking about being able to shorten that period or move forward to rate adjustments in a faster pace?
Sarah James: Thank you. Can you help us understand the mechanics of the actuarial soundness look-back process? Like, how far back are they looking now? How long of a lag does that typically take to come to an agreement on what trends actually were? And as we move forward into continued periods of disruption through work requirements or additional redeterminations, how are you thinking about being able to shorten that period or move forward to rate adjustments in a faster pace?
Thank you. Our next question today comes from James, to cancel order. Please go ahead.
Thank you. Can you help us understand the mechanics of the actual soundness look-back process? Like, how far back are they looking now? How long of a lag does that typically take to come to an agreement on what transactions actually were? And as we move forward into continued periods of disruption through work requirements or additional redetermination, how will that affect the process?
Sarah London: Yeah. Thanks, Sarah. It's a great question. The short answer is that we are very focused on trying to shorten the period and maximize the amount of sort of most recent data that's being included in the actuarial process. But this is not a new thing, right? That has really been what we have been working on since the back half of 2024, as we started to see that dislocation between rates and acuity from redeterminations, and then the step up in trend that we saw in 2025. And so, as we've said, you know, we continue to very proactively engage with the states. We're obviously not alone in doing that, so our peers are also part of that conversation, bringing forward, you know, most recent data, direct correlation to the program changes.
Sarah London: Yeah. Thanks, Sarah. It's a great question. The short answer is that we are very focused on trying to shorten the period and maximize the amount of sort of most recent data that's being included in the actuarial process. But this is not a new thing, right? That has really been what we have been working on since the back half of 2024, as we started to see that dislocation between rates and acuity from redeterminations, and then the step up in trend that we saw in 2025. And so, as we've said, you know, we continue to very proactively engage with the states. We're obviously not alone in doing that, so our peers are also part of that conversation, bringing forward, you know, most recent data, direct correlation to the program changes.
How are you thinking about, uh, being able to shorten that period or, um, move forward to rate adjustments at a faster pace?
Yeah, thanks, Sarah, it's a great question. The short answer is that we are very focused on, um, trying to shorten the period and maximize the amount of, uh, sort of most recent data that's being included in the actuarial process.
Sarah London: If I take a step back, I think that, you know, the perhaps the silver lining of what has been a bit of a painful process to watch these rates lag is the fact that we have now sort of proof points that you can actually have, you know, a significant forward-looking trend in ABA, unlike anything the actuaries had ever seen before. We do have the proof points of states actually bringing forward more recent data and making in-year adjustments. Again, the Florida CMS contract in Q3 of last year is a great example of that. That was a very quick turnaround time between observed behavior and rate correction. And so all of those lessons learned, we carry into the work that we're gonna wanna do in 2026.
Sarah London: If I take a step back, I think that, you know, the perhaps the silver lining of what has been a bit of a painful process to watch these rates lag is the fact that we have now sort of proof points that you can actually have, you know, a significant forward-looking trend in ABA, unlike anything the actuaries had ever seen before. We do have the proof points of states actually bringing forward more recent data and making in-year adjustments. Again, the Florida CMS contract in Q3 of last year is a great example of that. That was a very quick turnaround time between observed behavior and rate correction. And so all of those lessons learned, we carry into the work that we're gonna wanna do in 2026.
But this is not a new thing, right? That is that has really been what we have been working on, um, since the back half of 2024, as we started to see that dislocation between rate and Acuity from redetermination. And then the Step Up in Trend that we saw in 2025. And so, as we've said, you know, we continue to very proactively engage with states where obviously not alone in doing that. So, our peers, um, are also part of that conversation, um, bringing forward, you know, most recent data direct correlation to the program changes. If I take a step back, I think that, you know, this, perhaps the silver lining of um what has been a bit of a painful process to watch these rates. Lag is the fact that we have now, sort of proof points that you can actually have, you know, a significant forward-looking Trend in ABA unlike anything the actuaries had ever seen before. Um, you we do have the proof points of States actually bringing forward more.
Sarah London: to try to preempt the changes that may come in 2027 and 2028, and make sure that we have appropriate rates as we think about what the impact of work requirements are gonna be. It's also why I keep pointing back to the fact that as time rolls forward, our need to push for, you know, that more recent data of being included is just happening organically. And so now, all those, those acuity shifts in 2024, the rate, sorry, the trend impact in 2025 is now basically sitting, you know, in the middle of that 2-year look-back period, which is probably the more conservative look-back period, or standard starting point for the actuarial process. But it is, you know, it's a dynamic process.
Sarah London: to try to preempt the changes that may come in 2027 and 2028, and make sure that we have appropriate rates as we think about what the impact of work requirements are gonna be. It's also why I keep pointing back to the fact that as time rolls forward, our need to push for, you know, that more recent data of being included is just happening organically. And so now, all those, those acuity shifts in 2024, the rate, sorry, the trend impact in 2025 is now basically sitting, you know, in the middle of that 2-year look-back period, which is probably the more conservative look-back period, or standard starting point for the actuarial process. But it is, you know, it's a dynamic process.
Recent data and making your adjustments. Again, the floor to CMS contract in Q3 of last year is a great example of that. That was a very quick turnaround time between observed behavior and great correction, and so all of those lessons learned we carry into the work that we're going to want to do in 2026.
To try to preempt.
Sarah London: It's why it has been really important for us to build and continue to have really strong relationships with our states, and to lean in and help them as they're going through that process by bringing forward very specific data. And then the last thing I would say is, you know, just to go back to Justin's question, is the idea that, you know, in the absence of rates, and the states are thinking about what budget pressures they may be facing, it's also a great moment to talk about where there are program refinement opportunities that get us back into sort of a reasonable cost of care that doesn't just come through the rate.
Sarah London: It's why it has been really important for us to build and continue to have really strong relationships with our states, and to lean in and help them as they're going through that process by bringing forward very specific data. And then the last thing I would say is, you know, just to go back to Justin's question, is the idea that, you know, in the absence of rates, and the states are thinking about what budget pressures they may be facing, it's also a great moment to talk about where there are program refinement opportunities that get us back into sort of a reasonable cost of care that doesn't just come through the rate.
Sarah London: So we're finding those conversations to be really productive, and seeing, again, some of those bankable proof points in the back half of 2025 that we think will bear fruit in 2026.
Sarah London: So we're finding those conversations to be really productive, and seeing, again, some of those bankable proof points in the back half of 2025 that we think will bear fruit in 2026.
Period, um, or standard starting point for the Actuarial process. Um, but it is, you know, it's a dynamic process. It's why it has been really important for us to build and continue to have really strong relationships with our states, um, and to lean in and help them. As they're going through that process, by bringing forward, very specific data. And then the last thing I would say is, you know, just to go back to Justin's question is the idea that, you know, in the absence of rates in the states are thinking about what budget pressures, they may be facing. It's also a great moment to talk about where there are program refinement opportunities that get us back into sort of a reasonable cost of care. That doesn't just come through the rate. And so we're finding those conversations to be really productive. Um, and seeing again, some of those bankable proof points in the back half of 2025 that we think will bear fruit in 2026.
Operator: Thank you. And our next question today comes from Joshua Raskin at Nephron Research. Please go ahead.
Operator: Thank you. And our next question today comes from Joshua Raskin at Nephron Research. Please go ahead.
Joshua Raskin: Hi, thanks. Good morning. Could you just give a little more specifics on your actual segment margins that are implied in the 2026 guidance, and then maybe remind us what your long-term margin targets are by segment, in case anything has changed there? And should I be reading into no PDR in Medicare Advantage, meaning that you may be closer to breakeven in 2026, you know, a little ahead of 2027?
Joshua Raskin: Hi, thanks. Good morning. Could you just give a little more specifics on your actual segment margins that are implied in the 2026 guidance, and then maybe remind us what your long-term margin targets are by segment, in case anything has changed there? And should I be reading into no PDR in Medicare Advantage, meaning that you may be closer to breakeven in 2026, you know, a little ahead of 2027?
Thank you. And our next question is from Joshua, asked in a restaurant. Please go ahead.
Sarah London: Yeah, so I think, obviously, a lot of stuff has changed across the business, so it's probably premature to talk about long-term margin targets for each business while policy is still shaking out. But the bottom line there is certainly that we do see opportunity for margin improvement in all lines of business, and meaningful margin improvement across the enterprise over the next couple of years. But let me turn it over to Drew to walk through the specific margin assumptions by line of business in 2026 guidance, and then talk through the PDR.
Sarah London: Yeah, so I think, obviously, a lot of stuff has changed across the business, so it's probably premature to talk about long-term margin targets for each business while policy is still shaking out. But the bottom line there is certainly that we do see opportunity for margin improvement in all lines of business, and meaningful margin improvement across the enterprise over the next couple of years. But let me turn it over to Drew to walk through the specific margin assumptions by line of business in 2026 guidance, and then talk through the PDR.
Hi, thanks. Good morning. Um, could you just give a little more specifics on your actual segment margins that are implied in the 2026 guidance? And then maybe remind us what your long-term margin targets are by segment, in case anything has changed there? And should I be reading into no PDR in Medicare Advantage, meaning that you may be closer to break-even in 2026, you know, a little ahead of 2027?
Andrew Asher: Yeah, sure. I'd express, you know, Medicaid margins in terms of a stable HBR year-over-year. The commercial segment, which is largely marketplace, we were at -1% last year. You could do the math on the HBR guidance slide and get to something, you know, around 4%, for 2026 in marketplace. And then the Medicare segment, as I said in my remarks, PDP around 2% would be our target. We think that's a prudent starting place relative to, you know, well into the 3s for 2025. And then Medicare Advantage within that segment, not quite at breakeven yet, but you're right to recognize no PDR in 2026, means that on the margin, it's not losing money.
Drew Asher: Yeah, sure. I'd express, you know, Medicaid margins in terms of a stable HBR year-over-year. The commercial segment, which is largely marketplace, we were at -1% last year. You could do the math on the HBR guidance slide and get to something, you know, around 4%, for 2026 in marketplace. And then the Medicare segment, as I said in my remarks, PDP around 2% would be our target. We think that's a prudent starting place relative to, you know, well into the 3s for 2025. And then Medicare Advantage within that segment, not quite at breakeven yet, but you're right to recognize no PDR in 2026, means that on the margin, it's not losing money.
Yeah, so I think, uh, obviously a lot of stuff has changed across the business, so it's probably premature to talk about long-term margin targets for each business while policy is still shaking out. But the bottom line there is certainly that we do see opportunity for margin improvement in all lines of business and meaningful margin improvement across the enterprise over the next couple of years. But let me turn it over to Drew to walk through the specific margin assumptions by line of business in 2026 guidance, um, and then talk through the PDR. Yeah, sure. I, I express, you know, Medicaid, um,
Margins, in terms of a stable HBR year-over-year.
Andrew Asher: But, you know, there are things that aren't incorporated in the accounting of the PDR, such that it's still operating at a slight loss on a fully allocated basis for 2026.
Drew Asher: But, you know, there are things that aren't incorporated in the accounting of the PDR, such that it's still operating at a slight loss on a fully allocated basis for 2026.
Which is largely Marketplace. We were at minus 1 last year. You could do the math on the hbr, guidance slide and get to something, you know, around 4% uh pre-tax for 2026 in Marketplace and then the Medicare segment. Uh as I said in my remarks PDP around 2% would be our Target. We think that's a prudent. Starting Place relative to you know, well into the 3s for 2025 um, and then Medicare Advantage within that segment. Not quite at break even yet, but you're right to recognize, no PDR in 2026 means that on the margin. It's not losing money but you know, there are things that aren't Incorporated in the accounting of the PDR such that it's still operating at a slight loss, uh, on the
Fully allocated basis for 2026.
Operator: Thank you. Our next question today comes from AJ Rice, UBS. Please go ahead.
Operator: Thank you. Our next question today comes from AJ Rice, UBS. Please go ahead.
AJ Rice: Thanks. Hi, everybody. You know, we still are trying, and I still get this question a lot, maybe an unfair one to ask you guys, but I'll do it anyway. If you look at your national peers in Medicaid, two are still forecasting pretty significant drops in margin in 2026 versus 2025. One, who was more optimistic, has now sort of come in line with you with their comments today. And we all struggle to think about how can the company see such a different outlook. Do you think geographic footprint explains the difference, or is there anything else there?
A.J. Rice: Thanks. Hi, everybody. You know, we still are trying, and I still get this question a lot, maybe an unfair one to ask you guys, but I'll do it anyway. If you look at your national peers in Medicaid, two are still forecasting pretty significant drops in margin in 2026 versus 2025. One, who was more optimistic, has now sort of come in line with you with their comments today. And we all struggle to think about how can the company see such a different outlook. Do you think geographic footprint explains the difference, or is there anything else there?
Thank you. Our next question today comes from EJ Rice at CBS. Please go ahead.
Uh, thanks. Hi everybody. Um,
You know, we still are trying. Uh, and I still get this question a lot. Maybe it's an unfair one to ask you guys, but I'll do it anyway. Um,
AJ Rice: I specifically, in your case, wanted to ask about the PBM contract, because you haven't said a lot about it, but your vendor, your PBM partner, has said that they have renegotiated your contract among a couple other big ones, and that it's a drag to them this year. Presumably, you're on the receiving end of that and benefiting, and I wondered if that might be accounting for some of the difference, or maybe that's helping you in other business lines, but any comment on that as well would be helpful.
A.J. Rice: I specifically, in your case, wanted to ask about the PBM contract, because you haven't said a lot about it, but your vendor, your PBM partner, has said that they have renegotiated your contract among a couple other big ones, and that it's a drag to them this year. Presumably, you're on the receiving end of that and benefiting, and I wondered if that might be accounting for some of the difference, or maybe that's helping you in other business lines, but any comment on that as well would be helpful.
if you look at your National peers in Medicaid 2 or still forecasting, pretty significant drops in margin in 26, versus 25 1 who was more optimistic, uh, is now sort of come in line with you with their comments today. Um, and we all struggle to think about how can, uh, the companies, see, such a different Outlook, do you think, uh, Geographic footprint explains, uh, the difference, or is there anything else there? And I specifically in your case wanted to ask about the PBM contract because you haven't said a lot about it. But uh, your vendor your PBM partner has said that. They have renegotiated your contract among a couple other big ones and that it's a drag to them this year, presumably you're on the receiving end of that and benefiting and I wondered if that might be accounting for some of the difference, or maybe that's helping you in other
Sarah London: Yeah. Thanks, AJ. So let me hit Medicaid, and then I'll turn it over to Drew to talk about our bespoke contract with our PBM partner. So sort of going all the way back to where we're starting, which I think is really important. So again, it's important to remember that we are dropping off an elevated baseline. So as you think about trying to foot relativity with peers, just absolute, we are dropping off that elevated baseline in 2025, that included a 94.9 in Q2. We also have, you know, again, proof points, sort of rates that matured favorably as we in 2025, so that's an important thing to think about relative to that mid-4 rate assumption.
Sarah London: Yeah. Thanks, AJ. So let me hit Medicaid, and then I'll turn it over to Drew to talk about our bespoke contract with our PBM partner. So sort of going all the way back to where we're starting, which I think is really important. So again, it's important to remember that we are dropping off an elevated baseline. So as you think about trying to foot relativity with peers, just absolute, we are dropping off that elevated baseline in 2025, that included a 94.9 in Q2. We also have, you know, again, proof points, sort of rates that matured favorably as we in 2025, so that's an important thing to think about relative to that mid-4 rate assumption.
Business lines, but any comment on that as well would be helpful.
Yeah, thanks, AJ. So let me hit Medicaid, and then I'll turn it over to Drew to talk about our bespoke contract with our PBM partner. Um, so
Sarah London: And then we have, you know, aggressive execution through the back half of the year that played out, you know, with that sequential improvement in HBR in Q3 and in Q4, getting to that 93.0 as the jump-off as we step into 2026. And so that momentum, I think, is really important, and the fact that, you know, we laid out sort of the key levers that we were going after, and again, executed on those really well in Q3 and Q4, but also took action and influenced decisions in Q3 and Q4 that aren't effective, for example, until 1 January 2026. And so just as a reminder, right, in some of those proof points, rate, obviously an important one.
Sarah London: And then we have, you know, aggressive execution through the back half of the year that played out, you know, with that sequential improvement in HBR in Q3 and in Q4, getting to that 93.0 as the jump-off as we step into 2026. And so that momentum, I think, is really important, and the fact that, you know, we laid out sort of the key levers that we were going after, and again, executed on those really well in Q3 and Q4, but also took action and influenced decisions in Q3 and Q4 that aren't effective, for example, until 1 January 2026. And so just as a reminder, right, in some of those proof points, rate, obviously an important one.
Sarah London: The you know, favorable maturation of the 2025 composite, the fact that Q1 came in line with our expectation, the fact that we saw in-year rate correction like Florida. The second biggest lever is network. And again, you heard me talk about the ABA example, but really making sure that we focus our network on the highest performing, highest quality providers. The introduction of clinical management programs, you know, hitting transitions of care and member engagement. Program reform, I talked about a bunch of those. Ongoing provider engagement, payment integrity, and really addressing opportunities where we're seeing pressure on coding from providers. And then again, a more aggressive stance in fraud, waste, and abuse.
Sarah London: The you know, favorable maturation of the 2025 composite, the fact that Q1 came in line with our expectation, the fact that we saw in-year rate correction like Florida. The second biggest lever is network. And again, you heard me talk about the ABA example, but really making sure that we focus our network on the highest performing, highest quality providers. The introduction of clinical management programs, you know, hitting transitions of care and member engagement. Program reform, I talked about a bunch of those. Ongoing provider engagement, payment integrity, and really addressing opportunities where we're seeing pressure on coding from providers. And then again, a more aggressive stance in fraud, waste, and abuse.
Again, proof Point sort of rates that matured favorably as we in 2025. So that's an important thing to think about uh relative to that mid Force rate assumption and then we have, you know, aggressive execution, through the back half of the year that played out you know with that sequential Improvement in hbr in Q3 and and in Q4 getting to that 93 0 as the jump off, as we step into 2026. And so that momentum, I think is really important and the fact that, you know, we laid out sort of the, the key levers that we were going after. Um, and again, executed on those really well in Q3 and Q4, but also took action and influence, decisions in Q3 and Q4 that are an effective, for example, until 11126. And so just as a reminder, right in some of those proof points rate, obviously, an important 1, the the, you know, favorable maturation of the 2025 cons composite. The fact that 1 1 came in
In line with our expectation. The fact that we saw in your rate correction like Florida, the second biggest lever is network and again, you heard me talk about the ABA example, but really making sure that we focused our Network. On the highest performing highest quality providers, the introduction of clinical Management Programs, um, you know, hitting transitions of care and member engagement program reform. I I talked about a bunch of those ongoing provider, engagement payment, integrity, and really addressing opportunities where that we're seeing pressure on coding.
Sarah London: You heard us talk about, you know, a provider that we, we termed in New York back in Q3 around ABA, but really leveraging that suspect list to go after, bad actors. So a lot of proof points that, you know, that did actually hit the P&L in the back half of 2025 and are teed up for 2026. So that's where I think, you know, our view is that we've taken a prudent assumption around rates, that the net trend assumption of 4.5 in 2026 takes into account sort of the work that we've done relative to trend vendors and being able to see additional, you know, those actions bear additional fruit in 2026.
Sarah London: You heard us talk about, you know, a provider that we, we termed in New York back in Q3 around ABA, but really leveraging that suspect list to go after, bad actors. So a lot of proof points that, you know, that did actually hit the P&L in the back half of 2025 and are teed up for 2026. So that's where I think, you know, our view is that we've taken a prudent assumption around rates, that the net trend assumption of 4.5 in 2026 takes into account sort of the work that we've done relative to trend vendors and being able to see additional, you know, those actions bear additional fruit in 2026.
From providers. And then again a more aggressive stance in um in fraud waste and abuse and you heard us talk about uh you know, a provider that we we termed in New York back in Q3 around Abba, but really leveraging that suspect list to go after, um, Bad actors. So a lot of proof points that, you know, that did actually hit the p&l in the back after 25 and are teed up for 2026. So, that's where I think, you know, our view is that we've taken a prudent assumption around rates, um, that the net Trend Assumption of 4 and a half, um, in 2026,
Takes into account sort of the work that we've done?
Sarah London: I will say it again, because I will just keep saying it both internally and externally, if all we do is deliver a 93.7 in Medicaid, I will be very disappointed. With that, I will let Drew talk about our PBM relationship.
Sarah London: I will say it again, because I will just keep saying it both internally and externally, if all we do is deliver a 93.7 in Medicaid, I will be very disappointed. With that, I will let Drew talk about our PBM relationship.
Andrew Asher: Yeah, AJ, thanks for the question. Over the last really decade plus, we've had a tailored, transparent, and flexible contract with, like, our current PBM, even our predecessor PBM. So we had those provisions before they were cool and before they were legislatively dictated. I think we benefit by having $60 billion of pharmacy spend and not owning our own PBM. In other words, every ounce of the economic benefit of that PBM arrangement and how we collaborate with our partner to go to the market together, whether it's pharma or network or other decisioning around formulary benefit plan designs, we've got immense flexibility in how we work with our partner, and that goes into the cost structure of our products and our margin targets. So all of that is captured in our insurance risk business in our 3 segments.
Drew Asher: Yeah, AJ, thanks for the question. Over the last really decade plus, we've had a tailored, transparent, and flexible contract with, like, our current PBM, even our predecessor PBM. So we had those provisions before they were cool and before they were legislatively dictated. I think we benefit by having $60 billion of pharmacy spend and not owning our own PBM. In other words, every ounce of the economic benefit of that PBM arrangement and how we collaborate with our partner to go to the market together, whether it's pharma or network or other decisioning around formulary benefit plan designs, we've got immense flexibility in how we work with our partner, and that goes into the cost structure of our products and our margin targets. So all of that is captured in our insurance risk business in our 3 segments.
Relative to Trend vendors and being able to see additional—you know, those actions bear additional fruit in 2026. Um, and I will say it again because I will just keep saying it both internally and externally. If all we do is deliver a 937 in Medicaid, I will be very disappointed. But with that, I will let Drew talk about our PBM relationship. Yeah, AJ, thanks for the question. Uh, over the last, really, decade plus we've had a tailored, transparent, and flexible contract with our current PBM, even our predecessor PBM. So we had those provisions before they were cool and before they were legislatively dictated. I think we benefit by having $60 billion of pharmacy spend and not owning our own PBM. In other words, every—
Andrew Asher: Pleased with, you know, pleased with what we talked about last quarter in terms of the continued collaboration with our partner, and we will continue to fight for affordability in healthcare, you know, including other parts of the ecosystem that have margins, including one I saw on CNBC the other day, boasting about a 40% margin in his pharma business. So we will continue to drive affordability on behalf of our low income and medically complex members alongside with our PBM partner.
Drew Asher: Pleased with, you know, pleased with what we talked about last quarter in terms of the continued collaboration with our partner, and we will continue to fight for affordability in healthcare, you know, including other parts of the ecosystem that have margins, including one I saw on CNBC the other day, boasting about a 40% margin in his pharma business. So we will continue to drive affordability on behalf of our low income and medically complex members alongside with our PBM partner.
Ounce of the economic benefit of those that PBM arrangement and how we collaborate with our partner to go to the market together, whether it's pharma or network, or other decisioning around formulary benefit plan designs. We've got immense flexibility in how we work with our partner, and that goes into the cost structure of our products and our margin targets. So, all of that is captured in our insurance risk business in our three segments, and, uh, pleased with, you know, pleased with what we talked about last quarter in terms of the continued collaboration with our partner, and we will continue to fight for affordability and healthcare, you know, including other parts of the ecosystem that have margins, including one I saw on CNBC the other day, boasting about a 40% margin in his pharma business. So we will continue to drive affordability on behalf of our
low-income and medically complex members, alongside with our PVM partner.
Operator: Thank you. Our next question today comes from Scott Fidel with Goldman Sachs. Please go ahead.
Operator: Thank you. Our next question today comes from Scott Fidel with Goldman Sachs. Please go ahead.
Thank you.
Scott Fidel: Hi, thanks. Good morning. Michelle, help me if you maybe just sort of drill in a little bit more into Part D, and walk us through the book in terms of some of the dynamics through around the LIS versus the non-LIS populations and what you're seeing in the market trends. Obviously, your book of business heavily weighted towards the LIS, and in particular, just, you know, some of the underlying inputs like risk scores and economics in terms of the LIS business post IRA, versus the non-LIS, and then how you position the business, you know, to grow and be profitable clearly, through 25 and expecting you to do that in 26. Thanks.
Next question. Today comes from Scott Fidel with Goldman Sachs. Please go ahead.
Scott Fidel: Hi, thanks. Good morning. Michelle, help me if you maybe just sort of drill in a little bit more into Part D, and walk us through the book in terms of some of the dynamics through around the LIS versus the non-LIS populations and what you're seeing in the market trends. Obviously, your book of business heavily weighted towards the LIS, and in particular, just, you know, some of the underlying inputs like risk scores and economics in terms of the LIS business post IRA, versus the non-LIS, and then how you position the business, you know, to grow and be profitable clearly, through 25 and expecting you to do that in 26. Thanks.
Andrew Asher: Yeah, really good question, and questions, especially around the impact of the IRA in 25, which there were, you know, shifting sands. So the good news in 25 is the industry, we had that expanded or more protective risk corridor that then reverted in 26 back to the statutory risk corridor that's been in place since the inception of the Part D program. But that gave us some, let's say, breathing room in terms of navigating, pretty severe non-low-income specialty trend when the maximum amount of pocket dropped to $2,000. And so we got through that, executed really well. That's in the rear view mirror.
Drew Asher: Yeah, really good question, and questions, especially around the impact of the IRA in 25, which there were, you know, shifting sands. So the good news in 25 is the industry, we had that expanded or more protective risk corridor that then reverted in 26 back to the statutory risk corridor that's been in place since the inception of the Part D program. But that gave us some, let's say, breathing room in terms of navigating, pretty severe non-low-income specialty trend when the maximum amount of pocket dropped to $2,000. And so we got through that, executed really well. That's in the rear view mirror.
Expect to continue to do that in 2026. Thanks.
Andrew Asher: Now we and the rest of the industry had that data going into the bids in the summer of 2025 as we set them for 2026, with, you know, eyes wide open in terms of the impact of the IRA on that non-low-income population that, you know, was availing themselves of a much lower maximum out-of-pocket. So we can look at our January data, and you're right, we're growing. You know, the revenue growth is largely driven by that yield increase because of the direct subsidy increase, but we're still growing membership from about 8.1 to around 8.7 million across both the low-income population or the auto assigns and the non-low-income population. So feel pretty good about the mix of business we got. We like both populations.
Drew Asher: Now we and the rest of the industry had that data going into the bids in the summer of 2025 as we set them for 2026, with, you know, eyes wide open in terms of the impact of the IRA on that non-low-income population that, you know, was availing themselves of a much lower maximum out-of-pocket. So we can look at our January data, and you're right, we're growing. You know, the revenue growth is largely driven by that yield increase because of the direct subsidy increase, but we're still growing membership from about 8.1 to around 8.7 million across both the low-income population or the auto assigns and the non-low-income population. So feel pretty good about the mix of business we got. We like both populations.
Yeah, really good question. And it's a special questions, especially around the impact of the IRA in 25 which there were, you know, shifting Sands. So the good news in 25 is the industry. We had that expanded or more protective risk Corridor. That then reverted in 26, back to the statutory risk Corridor that's been in place since the Inception of the part D program, uh, but that gave us some, let's say Breathing Room in terms of navigating, um, pretty severe non- low-income specialty Trend when the maximum amount of pocket dropped to 2,000. And so we got through that executed really well, that's in the rearview mirror and now we and the rest of the industry, had that data going into the bids in the summer of 25 as we set them for 2026 with you know, eyes wide open in terms of the impact of the IRA on that non low income uh uh population that you know, was availing themselves of a much.
Lower maximum amount of pocket so we can look at our January data, and you're right. We're growing, you know, the, the revenue growth is largely driven by that yield increase because the direct subsidy increase, but we're still growing membership from about 8.1 to around 8.7 million, um, across both the low-income population or the Ottawa signs and the non- low-income population.
Andrew Asher: You can have earnings on both populations and provide a really great value proposition for the senior, giving them access to, you know, to a great drug program. So that, in conjunction with the answer to the last question, in terms of, you know, cost structure, is an important leg of the stool, the underwriting acumen, having great actuaries to support and business teams to support that product, which is now, you know, a $26 billion product for us with a, with a good margin as well. So we're, we're pretty pleased with that business, our positioning, and, and maybe most importantly, what we're able to do for seniors to have an affordable product in the open market.
Drew Asher: You can have earnings on both populations and provide a really great value proposition for the senior, giving them access to, you know, to a great drug program. So that, in conjunction with the answer to the last question, in terms of, you know, cost structure, is an important leg of the stool, the underwriting acumen, having great actuaries to support and business teams to support that product, which is now, you know, a $26 billion product for us with a, with a good margin as well. So we're, we're pretty pleased with that business, our positioning, and, and maybe most importantly, what we're able to do for seniors to have an affordable product in the open market.
Ation. So feel pretty good about the mix of business. We got we like both populations. You can have earnings on both populations and provide a really great value proposition for the senior giving them access to, uh, you know, to a great drug program. So that in conjunction with the answer to the last question in terms of, you know, cost structures and important leg of the stool, the underwriting Acumen having great actuaries to support and business teams to support that product, which is now, you know, 26 billion product for us with a uh, with a good margin as well. So we're we're pretty pleased with that business. Our positioning and and maybe most importantly, what we're able to do for seniors to have an affordable product, um, in the open market,
Operator: Thank you. Our next question today comes from Lance Wilkes with Bernstein. Please go ahead.
Operator: Thank you. Our next question today comes from Lance Wilkes with Bernstein. Please go ahead.
Lance Wilkes: Great, thanks. Wanted to talk a little on Medicaid, and if you could, could you walk through Medicaid trends, kind of 2025 contrast with 2026 in a couple different ways, because there's so many different moving elements. So I was interested in your views as to how much risk shift had impacted 2025, and if you saw any continued impacts in 2026 with that, and whether you're seeing any impacts, either negative or positive, from states making benefit design changes. And then I'm kind of assuming that the remainder would be sort of core trend. And so then if in core trend, you could kind of describe, oh, what's your, what's your experience with categories, your inpatient, outpatient, and/or units and, and cost inflation?
Lance Wilkes: Great, thanks. Wanted to talk a little on Medicaid, and if you could, could you walk through Medicaid trends, kind of 2025 contrast with 2026 in a couple different ways, because there's so many different moving elements. So I was interested in your views as to how much risk shift had impacted 2025, and if you saw any continued impacts in 2026 with that, and whether you're seeing any impacts, either negative or positive, from states making benefit design changes. And then I'm kind of assuming that the remainder would be sort of core trend. And so then if in core trend, you could kind of describe, oh, what's your, what's your experience with categories, your inpatient, outpatient, and/or units and, and cost inflation?
Thank you. Our next question today comes from Lance Wils with Thursday. Please go ahead.
Great, thanks. Um, I want to talk a little on Medicaid and, if you could, could you walk through Medicaid trends—kind of '25 contrast with '26—in a couple different ways? Because there are so many different moving elements, I was interested in your views as to how much risk shift had impacted '25, and if you see any continued impacts in '26 with A&D, and whether you're seeing any impacts, either negative or positive, from states making benefits design changes. And then I'm kind of assuming that...
Lance Wilkes: And maybe as a tag onto that, if you could just talk a little bit about what you're seeing as far as competitive dynamics in states, given the margin pressures in Medicaid. Are you seeing any issues with small plans not being able to fulfill obligations or any lack of folks stepping back up to try to renew contracts? Thanks.
Lance Wilkes: And maybe as a tag onto that, if you could just talk a little bit about what you're seeing as far as competitive dynamics in states, given the margin pressures in Medicaid. Are you seeing any issues with small plans not being able to fulfill obligations or any lack of folks stepping back up to try to renew contracts? Thanks.
Sarah London: Yeah, thanks, Lance. I'll hit that at a high level and have Drew chime in as well. So as we said, we did continue to see a low level of continued membership attrition through 2025, as states were getting tighter with their eligibility criteria, which I think naturally put some pressure on trend. Relative to core trend, the drivers were really consistent with what we called out throughout, you know, Q2 and rolling forward in terms of behavioral health, home health, and high-cost drugs.
Sarah London: Yeah, thanks, Lance. I'll hit that at a high level and have Drew chime in as well. So as we said, we did continue to see a low level of continued membership attrition through 2025, as states were getting tighter with their eligibility criteria, which I think naturally put some pressure on trend. Relative to core trend, the drivers were really consistent with what we called out throughout, you know, Q2 and rolling forward in terms of behavioral health, home health, and high-cost drugs.
Sarah London: Those did not materially shift over the course of the last three quarters of the year, with behavioral health really driving sort of 50% of that excess trend, ABA being sort of a primary underpinning of that, home health, and home and community-based services being another, and then those high-cost drugs. Relative to impact, those, you know, particularly the, those excess trend areas, were kind of how we chalked the field in terms of organizing, and looking to mitigate that trend. And so lots of proof points in the back half of 2025 in terms of actually being able to intervene, and help sort of moderate that trend, which is what contributed, at least in part, to ending the year at a 93.0.
Sarah London: Those did not materially shift over the course of the last three quarters of the year, with behavioral health really driving sort of 50% of that excess trend, ABA being sort of a primary underpinning of that, home health, and home and community-based services being another, and then those high-cost drugs. Relative to impact, those, you know, particularly the, those excess trend areas, were kind of how we chalked the field in terms of organizing, and looking to mitigate that trend. And so lots of proof points in the back half of 2025 in terms of actually being able to intervene, and help sort of moderate that trend, which is what contributed, at least in part, to ending the year at a 93.0.
Did continue to see sort of a, um, a low level of, uh, continued membership attrition through 2025, um, as states were getting tighter with their eligibility criteria, which I think naturally puts some pressure on, uh, on trend relative to core trends. Um, the drivers were really consistent with what we called out, uh, throughout, you know, Q2 and rolling forward, in terms of behavioral health, home health, and high-cost drugs. Those did not materially shift over the course of the last three quarters of the year, with behavioral health really driving sort of 50% of that excess trend—Abba being sort of a primary underpinning of that. Um, home health, um, and home and community-based services being another, and then those...
Sarah London: So again, feel good where we stand today in terms of having really solid visibility into the various forms of trend that are influencing the business and being organized around the levers that impact them. Relative to competitive dynamics, we are seeing that, you know, continued rate pressure is having an impact on different markets and certainly some of the smaller nonprofit plans. And frankly, that is an important, you know, input into states thinking about making sure that they're funding the program sufficiently so that they have a competitive marketplace and that members have the quality of services that they want and they deserve. And I think over time, you know, it is something that we would watch relative to potential membership growth if competitors choose to exit any of those geographies.
Sarah London: So again, feel good where we stand today in terms of having really solid visibility into the various forms of trend that are influencing the business and being organized around the levers that impact them. Relative to competitive dynamics, we are seeing that, you know, continued rate pressure is having an impact on different markets and certainly some of the smaller nonprofit plans. And frankly, that is an important, you know, input into states thinking about making sure that they're funding the program sufficiently so that they have a competitive marketplace and that members have the quality of services that they want and they deserve. And I think over time, you know, it is something that we would watch relative to potential membership growth if competitors choose to exit any of those geographies.
Sort of moderate that Trend, which is what contributed at least in part to ending the year at a 93. So, again, feel feel good where we stand today, in terms of having really solid visibility into the various forms of trend that are influencing the business and being organized around the levers, that impact them, um, relative to competitive Dynamics. Um, we are seeing that, you know, continued rate pressure, um, is having an impact on different markets and certainly, some of the, the smaller, um, nonprofit plans. Um, and frankly, that's that is an important, you know, input into States, thinking about making sure that their funding the program, sufficiently so that they have a competitive Marketplace and that members have the quality of services, um, that they that they want and they deserve. And and I think over time, you know, it's something that we would watch relative to potential membership growth. Um, if competitors choose
Andrew Asher: Yeah, just two quick things to add to that. Interesting facts relative to your question, Lance. Inpatient looks good in Medicaid, and then if you isolate our TANF population, the continuous TANF population, which is like 5 million members, so it's a statistically valid cohort, and you set aside behavioral health, that trend looks fine, looks normal, like it would historically. So that enables us to sort of zero in on, as Sarah said, both those areas that we started talking about and recognizing in Q2 of 2025, as well as policy, and product and benefit changes with our state partners to really, you know, zero in on what we need to do to pull those levers.
Drew Asher: Yeah, just two quick things to add to that. Interesting facts relative to your question, Lance. Inpatient looks good in Medicaid, and then if you isolate our TANF population, the continuous TANF population, which is like 5 million members, so it's a statistically valid cohort, and you set aside behavioral health, that trend looks fine, looks normal, like it would historically. So that enables us to sort of zero in on, as Sarah said, both those areas that we started talking about and recognizing in Q2 of 2025, as well as policy, and product and benefit changes with our state partners to really, you know, zero in on what we need to do to pull those levers.
To exit any of those geographies. Yeah. Just 2, quick things to add to that. Um, interesting facts, relative to your question. Lance uh, inpatient looks good in Medicaid and then if you isolate our tan of population, uh, The Continuous tan of population, which is like 5 million members, so it's a statistically, valid cohort. Um, and you set aside Behavioral Health, that Trend looks fine, looks normal. Uh, like it would historically, so that enables us to sort of
Zero in on, as Sarah said, both those areas that we started talking about and recognizing in Q2 of '25, as well as policy, uh, and product and benefit changes with our state partners to really, you know, zero in on what we need to do to pull those levers.
Operator: Thank you. And our next question today comes from Andrew Mok at Barclays. Please go ahead.
Operator: Thank you. And our next question today comes from Andrew Mok at Barclays. Please go ahead.
Andrew Mok: Hi, good morning. When I look at the segment MLR components embedded in guidance, the ACA improvement and Medicaid stability look consistent with prior commentary, but the guide seems to imply incremental pressure within Medicare Advantage beyond the PDP reset. So first, is that correct? And second, can you help us understand the sources of that pressure and what that means for your target to achieve breakeven in 2027? Thanks.
Andrew Mok: Hi, good morning. When I look at the segment MLR components embedded in guidance, the ACA improvement and Medicaid stability look consistent with prior commentary, but the guide seems to imply incremental pressure within Medicare Advantage beyond the PDP reset. So first, is that correct? And second, can you help us understand the sources of that pressure and what that means for your target to achieve breakeven in 2027? Thanks.
Thank you. And our next question for today. Comes from Andrew Mark at barklay, please. Go ahead.
Andrew Asher: Yeah, I think you'd have to understand bifurcating under Medicare; we absolutely expect progression in Medicare Advantage, meaning improvement in that HBR. PDP, yes, there's a piece of going from, you know, well into the threes pre-tax margin to 2%, and that's HBR related. But also think about the math on the direct subsidy going from $143 to $200. And as I said in my script, you know, roll that through a PNL and the yield impact, where you need zero incremental admin for that. So you're increasing premium revenue, you're increasing medical costs. That has a mathematical impact on the HBR. That's embedded in that 35 basis points segment impact on the consolidated HBR as well. So I think that might be the missing piece, Andrew, of what you're trying to achieve.
Drew Asher: Yeah, I think you'd have to understand bifurcating under Medicare; we absolutely expect progression in Medicare Advantage, meaning improvement in that HBR. PDP, yes, there's a piece of going from, you know, well into the threes pre-tax margin to 2%, and that's HBR related. But also think about the math on the direct subsidy going from $143 to $200. And as I said in my script, you know, roll that through a PNL and the yield impact, where you need zero incremental admin for that. So you're increasing premium revenue, you're increasing medical costs. That has a mathematical impact on the HBR. That's embedded in that 35 basis points segment impact on the consolidated HBR as well. So I think that might be the missing piece, Andrew, of what you're trying to achieve.
Hi, good morning when I look at this segment mlr components embedded in Guidance, the ACA Improvement and Medicaid stability. Look consistent with prior commentary but the guide seems to imply incremental pressure within Medicare Advantage beyond the PDP reset. So first, is that correct? And second can you help us understand the sources of that pressure and what that means for your Target to achieve break even in 2027, thanks.
Yeah, I think you'd have to understand bifurcating under Medicare. We absolutely expect progression in Medicare Advantage, meaning improvement in that HBR PDP. Yes, there's a piece of going from, you know, well into the 3s pre-tax margin to 2%, and that's HBR-related. But also think about the math on the direct subsidy going from $143 to $200. And as I said in my script, you know, roll that through a P&L and the yield impact, where you need zero incremental admin for that. So you're increasing premium revenue, you're increasing medical costs—that has a mathematical in—
Impact on the hbr. That's embedded in that 35 basis points.
Segment impact on the consolidated HBR as well. So, I think that might be the missing piece, Andrew, of what you're trying to achieve.
Operator: Thank you. And our final question today comes from Dave Windley at Jefferies. Please go ahead.
Operator: Thank you. And our final question today comes from Dave Windley at Jefferies. Please go ahead.
Dave Windley: Thanks for squeezing me in. I wanted to come back to Exchange. Bronze, I think bronze margins have been a little more volatile, or MLRs have been more volatile in the past. You're seeing trade down, as I think a lot of people expected. I'm wondering if you have enough data so far to see whether the utilization patterns of those, you know, buy down bronze members are meeting your expectations. Are they, you know, is their gross medical costs declining because the individual bears more of the cost in bronze, things like that? I'm just wondering what that trade down profile looks like. Thank you.
Dave Windley: Thanks for squeezing me in. I wanted to come back to Exchange. Bronze, I think bronze margins have been a little more volatile, or MLRs have been more volatile in the past. You're seeing trade down, as I think a lot of people expected. I'm wondering if you have enough data so far to see whether the utilization patterns of those, you know, buy down bronze members are meeting your expectations. Are they, you know, is their gross medical costs declining because the individual bears more of the cost in bronze, things like that? I'm just wondering what that trade down profile looks like. Thank you.
Thank you. And our final question today comes from Dave, windley. It's Jeffrey. Please go ahead.
Sarah London: Yeah, thanks, Dave. So I would say, in general, sort of the-- what we're seeing in terms of trade down, again, sort of largely consistent with what we would have expected. We expect that it's probably a market dynamic as well, and, you know, was contemplated as we thought about overall pricing, and then taking into account not just how the Bronze products have operated over the last, you know, 5 years, but what they did pre-COVID and making... Or sorry, pre-EAPTCs and pre-COVID, and making sure that that was part of the calculus. It's obviously very, very early. We have not closed January yet, but I would say, based on a very early look, nothing alarming relative to utilization patterns.
Sarah London: Yeah, thanks, Dave. So I would say, in general, sort of the-- what we're seeing in terms of trade down, again, sort of largely consistent with what we would have expected. We expect that it's probably a market dynamic as well, and, you know, was contemplated as we thought about overall pricing, and then taking into account not just how the Bronze products have operated over the last, you know, 5 years, but what they did pre-COVID and making... Or sorry, pre-EAPTCs and pre-COVID, and making sure that that was part of the calculus. It's obviously very, very early. We have not closed January yet, but I would say, based on a very early look, nothing alarming relative to utilization patterns.
Thanks for squeezing me in. I wanted to come back to exchange. Um, bronze. I think bronze. Um, margins have been a little more volatile, volatile or mlrs have been more volatile in the past that you're, you're seeing trade down. As I think, a lot of people expected. I'm wondering if you have enough data, um, so far to see whether the utilization patterns of those. Um, those you know, buy down, bronze members are meeting your expectations. Are they, you know, is their gross medical cost declining because the individual Bears more of the cost, in bronze, things like that. I'm just wondering what that trade down profile. Looks like thank you.
And, Preco, um, and making sure that that was part of the calculus. It's obviously very, very early. We have not closed January yet. But I would say, um, based on a very early look, nothing alarming relative to utilization patterns.
Operator: Thank you. This concludes our question and answer session. I'd like to turn the conference back over to Sarah London for closing remarks.
Operator: Thank you. This concludes our question and answer session. I'd like to turn the conference back over to Sarah London for closing remarks.
Sarah London: Thanks, Rocco. Thank you all for your time and interest this morning. Despite the challenges of 2025, we entered 2026 with increased visibility and important momentum. I believe that we are well positioned to drive margin improvement in 2026 and over the next few years, while ensuring access to high quality, affordable healthcare for the members and communities we serve. And finally, to my Centene colleagues, I just want to say thank you for your incredible resilience and commitment. I am excited to see what we can deliver this year. And in the words of my legendary hometown quarterback, "Let's go!" Back to you, Rocco.
Sarah London: Thanks, Rocco. Thank you all for your time and interest this morning. Despite the challenges of 2025, we entered 2026 with increased visibility and important momentum. I believe that we are well positioned to drive margin improvement in 2026 and over the next few years, while ensuring access to high quality, affordable healthcare for the members and communities we serve. And finally, to my Centene colleagues, I just want to say thank you for your incredible resilience and commitment. I am excited to see what we can deliver this year. And in the words of my legendary hometown quarterback, "Let's go!" Back to you, Rocco.
Thank you. This is a looser question-and-answer session. I'd like to turn the conference back over to Sarah London for closing tomorrow.
Thank you all for your time and interest this morning.
Despite the challenges of 2025, we entered 2026 with increased visibility and important momentum. I believe that we are well positioned to drive margin improvement in 2026 and over the next few years, while ensuring access to high-quality and affordable health care for the members and communities we serve.
And finally, to my son team colleagues, I just want to say thank you for your incredible resilience and commitment. I am excited to see what we can deliver this year and in the words of my legendary Hometown quarterback. Let's go.
Operator: Thank you. Everyone, this concludes today's conference call. We thank you all for attending today's presentation. You may now disconnect your lines and have a wonderful day.
Operator: Thank you. Everyone, this concludes today's conference call. We thank you all for attending today's presentation. You may now disconnect your lines and have a wonderful day.
Back to you, Rocco.
Thank you, everyone. This concludes today's conference call. We thank you all for attending today's presentation. You may have a connection lines and have a wonderful day.
